Dr Nikki Verrills

Dr Nikki Verrills

ARC Future Fellow

School of Biomedical Sciences and Pharmacy (Medical Biochemistry)

Honing in on her target

Dr Nikki Verrills' research into a key signalling switch in cancer cells could provide an important breakthrough in treatment.

Nikki Verrills in the laboratory 

As a young undergraduate studying science, Dr Nikki Verrills had intentions of transferring to medicine. Then, she discovered a passion for laboratory research and realised she could effectively fight disease on another front.

"In the end I have achieved the best of both worlds," the biochemist and cancer researcher points out. "I am still in the medical field helping patients by contributing to the development of better treatments but I am also able to pursue my interest in lab work, which I find fascinating."

Verrills has certainly found her niche. Since completing her PhD in 2005 she has worked largely full-time in academic research, collecting a clutch of early career awards, fellowships and major grants in recognition of her groundbreaking research into leukaemia and breast cancer. She studies the molecular pathways of cancer, identifying genes and proteins in cancer cells in order to make comparisons between normal cells and cancer cells. She also analyses differences between cancer cells that respond well to drug treatments and those that do not.

"If scientists can identify proteins that are different in cancerous cells, or in drug-resistant cells, then we can design drugs to target those differences – drugs that will specifically kill cancerous cells but not normal cells," she explains. "That is fundamental cancer research, but most cancer drugs work by turning off a particular protein, or inactivating it. What is novel about our work is that we have targeted a protein that needs to be switched back on."

That protein is phosphatase 2A, or PP2A, which comes from a class of proteins known as 'tumour suppressors'. Normally, they act as a stop signal to inhibit the growth of cancerous cells. In leukaemia cells, however, PP2A is inactive, so the cancer cells continue to proliferate.

In 2007, Verrills worked with collaborators in the United States to prove that the drug FTY720 could effectively switch PP2A on in patients with chronic myeloid leukaemia (CML) – therefore stopping the cancer's spread without affecting the body's healthy cells. This year she was awarded a $360,000 grant from the Cure Cancer Australia Foundation and Cancer Council NSW to apply that research to a different cancer, acute myeloid leukaemia (AML), which has a very poor survival rate.

"There is a real urgency to find new treatments for AML because the vast majority of patients are resistant to chemotherapy and will die of the disease," Verrills asserts. The grant will allow Verrills and her team to test FTY720 and other drugs in different sub-types of AML, and move their work from the laboratory into clinical trials.

"Another focus of our work is establishing exactly how these types of drugs work," she outlines. "We know the end result is that they increase activity of PP2A but we want to advance the knowledge in this field by finding out specifically how they do that. Also, we know from literature that this class of proteins is important in a lot of solid tumours, so it is likely that this research will be applicable to other cancers as well."

Verrills has received ongoing support from high-profile national cancer organisations and has forged collaborations with key research groups in Australia and internationally. She also works closely with colleagues in the University's Centres for Cancer and Chemical Biology and through her links with the Hunter Medical Research Institute (HMRI) has established important working relationships with cancer specialists and haematologists. Her articles are published in internationally prominent journals and she has been recognised with a Voiceless Eureka Prize for Research for her commitment to minimising the use of animals in laboratory work. 

Verrills' doctoral studies into chemotherapy resistance in childhood leukaemia led to a Peter Doherty Postdoctoral Fellowship from the National Health and Medical Research Council in 2006. In the same year she was the inaugural recipient of a Hunter Medical Research Foundation grant for young cancer researchers. She is currently supported by an Early Career Researcher Fellowship with the Cancer Institute of NSW.

Verrills gained exposure during her doctoral studies to cutting-edge scientific techniques used at the Australian Proteomic Analysis Facility, in Sydney, becoming one of the first researchers in the country to use Difference In-Gel Electrophoresis (DIGE). This technique allows simultaneous analysis of proteins in cancerous, non-cancerous and control cells and vastly improves the efficiency and accuracy of testing.

The scientist admits that work/life balance is an elusive concept given her demanding research career, two young daughters and family interest in a vineyard (in which her husband Michael De Iuliis, a fellow scientist, is chief winemaker). But she praises the support of the University of Newcastle, which has allowed her to maintain the momentum of her research while juggling life's other commitments.

"Not only has the University supported me but it has also shown a lot of confidence in me, which is critical for career advancement," Verrills acknowledges. "I have my own research group and I have reached the stage of being an independent researcher much earlier than I probably would have anywhere else."

Visit the Priority Research Centre for Cancer

Visit the Priority Research Centre for Chemical Biology

Visit the HMRI website

Nikki Verrills in the laboratory

Honing in on her target

Dr Nikki Verrills’ research into a key signalling switch in cancer cells could provide an important breakthrough in treatment.

Read more

Career Summary

Biography

Dr Verrills research interests centre on understanding the signalling pathways involved in cancer development, progression and resistance to chemotherapy induced cell death. Her research involves cell biology and biochemistry, translation into clinically relevant mouse models of disease, and analysis of primary patient samples. During her PhD studies Dr Verrills used powerful proteomics techniques, including being one of the first in Australia to use difference in-gel electrophoresis (DIGE) technology, to discover novel protein alterations that confer chemotherapy resistance in childhood leukaemia.

In postdoctoral studies Dr Verrills further applied her proteomics skills to the investigation of respiratory disease, and has identified clinical biomarkers for asthma and chronic obstructive pulmonary disease. These proteins are now targets for patent applications and ongoing investigations into the development of diagnostics and improved therapies. Her postdoctoral studies in respiratory disease led to an interest in signalling pathways, with particular interest in the multifunctional protein phosphatase, PP2A. This led her to establish a research group investigating the role of protein phosphatase 2A (PP2A) in cellular functions. Her group has discovered novel roles for PP2A in cellular function and disease, including myeloid leukaemias, melanoma and asthma, and demonstrated that PP2A activation is a potential strategy for improved therapies (e.g. senior author papers in Cancer Research and Cell Signalling, and co-authored papers in Nature Medicine, Journal of Clinical Investigation; J Biol Chem; BBA; Cell Death & Diff). She has developed a unique panel of PP2A molecular reagents (shRNA, overexpression constructs, antibodies, pharmacological activators/inhibitors), and established strategic collaborations which has enabled her to expand her investigations of PP2A into the study of breast cancer.

Her PhD was awarded from Macquarie University in 2005, for which she received a Vice-Chancellor’s Commendation for Excellence in Research. In 2006 Dr Verrills received a highly competitive NHMRC Peter Doherty Postdoctoral Fellowship. Through this fellowship she also received a scholarship to the Australian Academy of Science “Science at the Shine Dome” meeting. In 2006 she also became the inaugural recipient of the Hunter Medical Research Institute (HMRI) Competitive Research Fund for Early Career Researchers in Cancer. In 2010 Dr Verrills was appointed to an ongoing academic position (Lecturer) at the University of Newcastle, however in 2011 she was awarded a Cancer Institute NSW Early Career Research Development Award, and after deferring this for a year for maternity leave, she took up this fellowship in Dec 2011.

Research outputs: Dr Verrills has 28 research publications, with 13 as first or senior author, appearing in journals of good to high impact in the field (average IF 6.4) and are well cited (>800 to date; average 59 cites/yr; h-index 14). The importance of her work has also been featured in editorial articles (Fojo, T (2006) J Natl Cancer Inst 98: 1363 and Ojima and Ferlini (2003) Chem Biol 10: 583).

Funding: Since 2006 Dr Verrills has attracted >$3M in competitive research grant/fellowship funding, from the NHMRC, Cancer Council NSW, Anthony Rothe Foundation, Ramaciotti Foundation, Cancer Institute NSW, Cure Cancer Australia Foundation, and the Hunter Medical Research Institute (HMRI). She has also attracted infrastructure funding from the ARC, ACRF, Ramaciotti Foundation and the Cancer Institute NSW of > $6.4M.

Awards: Dr Verrills research is internationally competitive and recognised through continued publications, presentations at international and national meetings, and international and national awards. These include the 2012 Newcastle Innovations ‘Rising Star Award’; 2010 HUPO Young Guns Award; 2007 Voiceless Eureka Prize; the 2007 Young Tall Poppy Award; the 2007 University of Newcastle Vice Chancellor’s Award for Research Excellence; 2004 Biochemical Journal Young Investigator Award, presented to the best young researcher at the 12th International Conference on Second Messengers and Phosphoproteins, Montreal, Canada; the Merck Sharp Dohm “Best of the Best” Award and the Cure Cancer Australia Foundation Award, both presented at the 2004 Australian Health and Medical Research (ASMR) Congress. In 2003 Dr Verrills was awarded the University of Sydney Medal for Excellence in Medical Research, presented to the best young researcher at the ASMR NSW Conference, and was a finalist in the Cure Cancer Australia Foundation’s Young Researcher of the Year Award.

Service to the discipline: Her expertise in the field of proteomics and cancer biology results in invitations to peer review grant applications (e.g. NHMRC, ARC, Wellcome Trust; AICR; Cure Cancer Australia Foundation), ~20 manuscripts/year for a variety of journals (e.g. Blood, Oncogene, Cancer Research; Molecular Cancer Therapeutics; Proteomics), and ~2 PhD theses/year. In 2012 and 2013 Dr Verrills was a panel member for the NHMRC Cancer Biology & Oncology grant review panel. She has also served on the Leukaemia Foundation PhD and Postdoctoral fellowship review panels. Dr Verrills is a mentor in a University run mentoring program for early career researchers, and has given many lectures to undergraduate, graduate, and school students on careers in medical research.

Invited presentations: In 2012 Dr Verrills was an invited speaker at the International meetings: Phophatases in Disease, Vic; 37th Annual Lorne Proteins Meeting, Vic; Garvan Signalling Meeting, Sydney; Australian Society for Medical Research (ASMR) NSW Branch Scientific Meeting, Sydney. She was also session chair for the ASMR NSW Branch Scientific Meeting and the New Directions in Leukaemia Research, Sunshine Coast. She regularly presents her research to other universities and research institutes. For example, in 2012 she presented at the Lowy Cancer Centre, UNSW, in 2010 at IMVS, Adelaide, and at Pharmaxis in Sydney. In past years she has presented at Macquarie University, The Oncology Research Unit, Westmead, and the Children’s Cancer Institute Australia, Sydney.

Student Supervision: Dr Verrills has been primary supervisor for 3 PhD students to completion, and a further student recently submitted. These students received a number of awards during their studies. She has supervised four Honours students (all received 1st Class).

Conference coordination: Dr Verrills was co-convenor for the international meeting: HMRI Translational Cancer Conference – Pathways to Tailored Therapies, Newcastle, 2008, and was on the organising committee for the 2006 HMRI Conference on Translational Cancer Research and again for the 2013 Conference.

Committees: Dr Verrills is an active member of the Hunter Medical Research Institute Cancer Research Program Steering committee, where she has taken a major role in building up the activities of the program including preparing strategic plans, infrastructure and program funding applications, inviting speakers and establishing an annual research seminar day to foster internal research collaborations. She is also a member of the University of Newcastle’s Australian Biomolecular Research Facility steering committee.

Community engagement: She has a strong commitment to the advancement and promotion of medical research in our society. As part of her community involvement she has disseminated her research through the print, radio, and television media, and has presented her research to the local community as a guest speaker at Rotary and Lions Clubs, and HMRI, Cure Cancer Australia, and Cancer Council NSW charity events. Through the Tall Poppy Campaign she has also presented her research to High School students across NSW, and has established relationships with her local school communities to foster and encourage an interest in studying science.

Current position: In Dec 2011 Dr Verrills returned from maternity leave as a Research Only Academic at the University of Newcastle, working 0.6FTE, funded by a Cancer Institute NSW ECR Development Award.

Research Expertise
Dr Verrills research interests centre on understanding the molecular changes involved in cancer progression and chemotherapy resistance. By using powerful proteomics techniques, including being one of the first in Australia to use difference in-gel electrophoresis (DIGE) technology, she has discovered novel protein alterations that confer chemotherapy resistance in childhood leukaemia. These proteins are now targets for ongoing investigations to develop improved therapies for relapsed leukaemia patients. Dr Verrills is currently investigating the role of the signaling protein, protein phosphatase 2A, in cancer. Using shRNA and overexpression transfection of normal and cancer cell lines, coupled with molecular and biochemical analyses such as PCR, immunoblotting, immunoprecipitation, immunofluorescence, 2D-DIGE and mass spectrometry, she is determining the role of mutant PP2A and specific PP2A subunits in the development of leukaemia and breast cancer.

Teaching Expertise
Dr Verrills is a strong supporter of fostering research students. She has supervised two Honours student (both received 1st Class), and is currently supervising one Honours and three PhD students. Dr Verrills is a fulltime research academic, however she does guest lecture for 2nd and 3rd year BBiomed Sci courses in Proteomics, Bioinformatics, Cancer, and Drug Resistance.

Administrative Expertise
Dr Verrills undetakes many administrative tasks, including managing the budgets for her grants. Some duties include obtaining product quotes, ordering, safety and ethics applications, co-ordinating multi investigator grant applications, and organising research seminar series and workshops.



Qualifications

  • PhD, Macquarie University
  • Bachelor of Science (Honours), Macquarie University

Keywords

  • Cancer
  • Leukaemia
  • Proteomics
  • Breast Cancer
  • Drug resistance
  • Signal transduction
  • Protein phosphatase 2A
  • Chemotherapy resistance

Fields of Research

Code Description Percentage
060199 Biochemistry and Cell Biology not elsewhere classified 75
111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified 15
111299 Oncology and Carcinogenesis not elsewhere classified 10

Professional Experience

Academic appointment

Dates Title Organisation / Department
21/05/2015 - 21/06/2015 Postdoctoral Scientist University of Newcastle
Australia
1/01/2012 - 31/12/2013 Membership - NHMRC Grant Review Panel NHMRC Grant Review Panel
Australia
1/01/2011 -  Fellow University of Newcastle
School of Biomedical Sciences and Pharmacy
Australia
1/01/2011 -  Cancer Institute NSW ECD Research Fellow Family Action Centre University of Newcastle
Australia
1/01/2006 - 1/07/2010 Peter Doherty Biomedical Fellow

NHMRC - Early Career Fellowships (Formerly Postdoctoral Training Fellowships)

National Health & Medical Research Council
1/01/2001 -  Membership - Australian Society for Medical Research Australian Society for Medical Research (ASMR)
Australia
1/01/1999 - 2/01/2001 Research Assistant Macquarie University
Australia

Membership

Dates Title Organisation / Department
Organising Committee Member - HMRI Conference on Translational Cancer Research Hunter Medical Research Institute (HMRI)
Australia
Committee Member - HMRI Cancer Research Group Steering Committee Hunter Medical Research Institute (HMRI)
Australia
Member - American Association of Cancer Research American Association of Cancer Research
United States

Awards

Honours

Year Award
1998 Bill Cantwell prize for Excellence in Biology
Macquarie University

Recipient

Year Award
2003 Australian Postgraduate Award 2001-2003
Macquarie University
2003 Australian Proteome Analysis Facility Scholarship 2001-2003
Australian Proteome Analysis Facility

Recognition

Year Award
2005 2005 - Doctor of Philosophy, Vice Chancellor Commendation.
Macquarie University
2003 2003 - Cure Cancer Australia Foundation's Young Researcher of the Year Award - Finalist.
Cure Cancer Australia Foundation

Research Award

Year Award
2004 2004 - Cure Cancer Australia Foundation Award
Cure Cancer Australia Foundation
2004 Biochemical Journal Young Investigator Award - 12th International Conference on Second Messengers and Phosphoproteins
The Biochemical Journal
2004 2004 - Merck Sharp Dohm 'Best of the Best' Award - Australian Health and Medical Research Congress
Australian Society of Medical Research
2003 2003 - University of Sydney Medal for Excellence in Medical Research
Australian Society of Medical Research

Invitations

Participant

Year Title / Rationale
2003 Protemics for cancer research
Organisation: Oncology Research Unit, Childrens Hospital, Westmead.
2003 Proteome analyses reveals novel mechanisms of resistance to anticancer agents.
Organisation: Oncology Research Unit, Childrens Hospital, Westmead.
2003 Amersham Biosciences Technical Seminar Series. Brisbane; Adelaide; Melbourne; Sydney.
Organisation: GE Biosciences Description: Amersham Biosciences, now part of GE Healthcare, is a world leader in proteomics technology. I was invited as an expert presenter on the use of state of the art proteomic technology, 2D difference gel electrophoresis, and how this technology can be applied in biomedical research.
2002 New technologies meets functional proteomics.
Organisation: ComBio 2002 Description: This was a special session at the ComBio meeting convened bythe Australian Proteomics Society and was an invited speaker.
Edit

Publications

For publications that are currently unpublished or in-press, details are shown in italics.


Chapter (1 outputs)

Year Citation Altmetrics Link
2011 Smith AM, Roberts KG, Verrills NM, 'Ser/Thr phosphatases: The new frontier for myeloid leukemia therapy?', Myeloid Leukemia - Basic Mechanisms of Leukemogenesis, Intech, Croatia 123-148 (2011) [B1]

Journal article (55 outputs)

Year Citation Altmetrics Link
2018 Almazi JG, Pockney P, Gedye C, Smith ND, Hondermarck H, Verrills NM, Dun MD, 'Cell-Free DNA Blood Collection Tubes Are Appropriate for Clinical Proteomics: A Demonstration in Colorectal Cancer.', Proteomics. Clinical applications, 12 e1700121 (2018) [C1]
DOI 10.1002/prca.201700121
Co-authors Craig Gedye, Hubert Hondermarck, Peter Pockney, Matt Dun
2018 Degryse S, De Bock CE, Demeyer S, Govaerts I, Bornschein S, Verbeke D, et al., 'Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia', Leukemia, 32 788-800 (2018) [C1]

© 2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved. Mutations in the interleukin-7 receptor (IL7R) or the Janus kinase 3 (JAK3) kinase occur frequen... [more]

© 2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved. Mutations in the interleukin-7 receptor (IL7R) or the Janus kinase 3 (JAK3) kinase occur frequently in T-cell acute lymphoblastic leukemia (T-ALL) and both are able to drive cellular transformation and the development of T-ALL in mouse models. However, the signal transduction pathways downstream of JAK3 mutations remain poorly characterized. Here we describe the phosphoproteome downstream of the JAK3(L857Q)/(M511I) activating mutations in transformed Ba/F3 lymphocyte cells. Signaling pathways regulated by JAK3 mutants were assessed following acute inhibition of JAK1/JAK3 using the JAK kinase inhibitors ruxolitinib or tofacitinib. Comprehensive network interrogation using the phosphoproteomic signatures identified significant changes in pathways regulating cell cycle, translation initiation, mitogen-activated protein kinase and phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/AKT signaling, RNA metabolism, as well as epigenetic and apoptotic processes. Key regulatory proteins within pathways that showed altered phosphorylation following JAK inhibition were targeted using selumetinib and trametinib (MEK), buparlisib (PI3K) and ABT-199 (BCL2), and found to be synergistic in combination with JAK kinase inhibitors in primary T-ALL samples harboring JAK3 mutations. These data provide the first detailed molecular characterization of the downstream signaling pathways regulated by JAK3 mutations and provide further understanding into the oncogenic processes regulated by constitutive kinase activation aiding in the development of improved combinatorial treatment regimens.

DOI 10.1038/leu.2017.276
Citations Scopus - 1Web of Science - 1
Co-authors Matt Dun
2017 Ong LK, Page S, Briggs GD, Guan L, Dun MD, Verrills NM, et al., 'Peripheral Lipopolysaccharide Challenge Induces Long-Term Changes in Tyrosine Hydroxylase Regulation in the Adrenal Medulla', Journal of Cellular Biochemistry, 118 2096-2107 (2017) [C1]

© 2016 Wiley Periodicals, Inc. Immune activation can alter the activity of adrenal chromaffin cells. The effect of immune activation by lipopolysaccharide (LPS) on the regulation ... [more]

© 2016 Wiley Periodicals, Inc. Immune activation can alter the activity of adrenal chromaffin cells. The effect of immune activation by lipopolysaccharide (LPS) on the regulation of tyrosine hydroxylase (TH) in the adrenal medulla in vivo was determined between 1 day and 6 months after LPS injection. The plasma levels of eleven cytokines were reduced 1 day after LPS injection, whereas the level for interleukin-10 was increased. The levels of all cytokines remained at control levels until 6 months when the levels of interleukin-6 and -4 were increased. One day after LPS injection, there was a decrease in TH-specific activity that may be due to decreased phosphorylation of serine 31 and 40. This decreased phosphorylation of serine 31 and 40 may be due to an increased activation of the protein phosphatase PP2A. One week after LPS injection, there was increased TH protein and increased phosphorylation of serine 40 that this was not accompanied by an increase in TH-specific activity. All TH parameters measured returned to basal levels between 1 month and 3 months. Six months after injection there was an increase in TH protein. This was associated with increased levels of the extracellular regulated kinase isoforms 1 and 2. This work shows that a single inflammatory event has the capacity to generate both short-term and long-term changes in TH regulation in the adrenal medulla of the adult animal. J. Cell. Biochem. 118: 2096¿2107, 2017. © 2016 Wiley Periodicals, Inc.

DOI 10.1002/jcb.25839
Co-authors Phil Dickson, Matt Dun, Linkooi Ong, Peter Dunkley
2017 Murray HC, Dun MD, Verrills NM, 'Harnessing the power of proteomics for identification of oncogenic, druggable signalling pathways in cancer', Expert Opinion on Drug Discovery, 12 431-447 (2017) [C1]

© 2017 Informa UK Limited, trading as Taylor & Francis Group. Introduction: Genomic and transcriptomic profiling of tumours has revolutionised our understanding of cancer. H... [more]

© 2017 Informa UK Limited, trading as Taylor & Francis Group. Introduction: Genomic and transcriptomic profiling of tumours has revolutionised our understanding of cancer. However, the majority of tumours possess multiple mutations, and determining which oncogene, or even which pathway, to target is difficult. Proteomics is emerging as a powerful approach to identify the functionally important pathways driving these cancers, and how they can be targeted therapeutically. Areas covered: The authors provide a technical overview of mass spectrometry based approaches for proteomic profiling, and review the current and emerging strategies available for the identification of dysregulated networks, pathways, and drug targets in cancer cells, with a key focus on the ability to profile cancer kinomes. The potential applications of mass spectrometry in the clinic are also highlighted. Expert opinion: The addition of proteomic information to genomic platforms¿¿proteogenomics¿¿is providing unparalleled insight in cancer cell biology. Application of improved mass spectrometry technology and methodology, in particular the ability to analyse post-translational modifications (the PTMome), is providing a more complete picture of the dysregulated networks in cancer, and uncovering novel therapeutic targets. While the application of proteomics to discovery research will continue to rise, improved workflow standardisation and reproducibility is required before mass spectrometry can enter routine clinical use.

DOI 10.1080/17460441.2017.1304377
Citations Scopus - 3Web of Science - 2
Co-authors Matt Dun
2017 Nair PM, Starkey MR, Haw TJ, Liu G, Horvat JC, Morris JC, et al., 'Targeting PP2A and proteasome activity ameliorates features of allergic airway disease in mice', Allergy: European Journal of Allergy and Clinical Immunology, 72 1891-1903 (2017) [C1]

© 2017 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd. Background: Asthma is an allergic airway disease (AAD) caused by aberrant immune responses to aller... [more]

© 2017 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd. Background: Asthma is an allergic airway disease (AAD) caused by aberrant immune responses to allergens. Protein phosphatase-2A (PP2A) is an abundant serine/threonine phosphatase with anti-inflammatory activity. The ubiquitin proteasome system (UPS) controls many cellular processes, including the initiation of inflammatory responses by protein degradation. We assessed whether enhancing PP2A activity with fingolimod (FTY720) or 2-amino-4-(4-(heptyloxy) phenyl)-2-methylbutan-1-ol (AAL(S)), or inhibiting proteasome activity with bortezomib (BORT), could suppress experimental AAD. Methods: Acute AAD was induced in C57BL/6 mice by intraperitoneal sensitization with ovalbumin (OVA) in combination with intranasal (i.n) exposure to OVA. Chronic AAD was induced in mice with prolonged i.n exposure to crude house dust mite (HDM) extract. Mice were treated with vehicle, FTY720, AAL(S), BORT or AAL(S)+BORT and hallmark features of AAD assessed. Results: AAL(S)reduced the severity of acute AAD by suppressing tissue eosinophils and inflammation, mucus-secreting cell (MSC) numbers, type 2-associated cytokines (interleukin (IL)-33, thymic stromal lymphopoietin, IL-5 and IL-13), serum immunoglobulin (Ig)E and airway hyper-responsiveness (AHR). FTY720 only suppressed tissue inflammation and IgE. BORT reduced bronchoalveolar lavage fluid (BALF) and tissue eosinophils and inflammation, IL-5, IL-13 and AHR. Combined treatment with AAL(S)+BORT had complementary effects and suppressed BALF and tissue eosinophils and inflammation, MSC numbers, reduced the production of type 2 cytokines and AHR. AAL(S), BORT and AAL(S)+BORT also reduced airway remodelling in chronic AAD. Conclusion: These findings highlight the potential of combination therapies that enhance PP2A and inhibit proteasome activity as novel therapeutic strategies for asthma.

DOI 10.1111/all.13212
Citations Scopus - 2Web of Science - 2
Co-authors Gang Liu, Malcolm Starkey, Nicole Hansbro, Philip Hansbro, Jay Horvat
2017 Watt LF, Panicker N, Mannan A, Copeland B, Kahl RGS, Dun MD, et al., 'Functional importance of PP2A regulatory subunit loss in breast cancer', Breast Cancer Research and Treatment, 166 117-131 (2017) [C1]

© 2017, Springer Science+Business Media, LLC. Purpose: Protein phosphatase 2A (PP2A) is a family of serine/threonine phosphatases that regulate multiple cellular signalling pathwa... [more]

© 2017, Springer Science+Business Media, LLC. Purpose: Protein phosphatase 2A (PP2A) is a family of serine/threonine phosphatases that regulate multiple cellular signalling pathways involved in proliferation, survival and apoptosis. PP2A inhibition occurs in many cancers and is considered a tumour suppressor. Deletion/downregulation of PP2A genes has been observed in breast tumours, but the functional role of PP2A subunit loss in breast cancer has not been investigated. Methods: PP2A subunit expression was examined by immunohistochemistry in human breast tumours, and by qPCR and immunoblotting in breast cancer cell lines. PP2A subunits were inhibited by shRNA, and mutant PP2A genes overexpressed, in MCF10A and MCF7 cells, and growth and signalling in standard and three-dimensional cultures were assessed. Results: Expression of PP2A-Aa, PP2A-Ba and PP2A-B'a subunits was significantly lower in primary human breast tumours and lymph node metastases, compared to normal mammary tissue. PP2A-Aa and the regulatory subunits PP2A-Ba, -Bd and -B'¿ were also reduced in breast cancer cell lines compared to normal mammary epithelial cells. Functionally, shRNA-mediated knockdown of PP2A-Ba, -B'a and -B'¿, but not PP2A-Aa, induced hyper-proliferation and large multilobular acini in MCF10A 3D cultures, characterised by activation of ERK. Expression of a breast cancer-associated PP2A-A mutant, PP2A-Aa-E64G, which inhibits binding of regulatory subunits to the PP2A core, induced a similar hyper-proliferative phenotype. Knockdown of PP2A-Ba also induced hyper-proliferation in MCF7 breast cancer cells. Conclusion: These results suggest that loss of specific PP2A regulatory subunits is functionally important in breast tumourigenesis, and support strategies to enhance PP2A activity as a therapeutic approach in breast cancer.

DOI 10.1007/s10549-017-4403-5
Citations Scopus - 2Web of Science - 2
Co-authors Matt Dun
2017 Ross EA, Naylor AJ, O'Neil JD, Crowley T, Ridley ML, Crowe J, et al., 'Treatment of inflammatory arthritis via targeting of tristetraprolin, a master regulator of pro-inflammatory gene expression', Annals of the Rheumatic Diseases, 76 612-619 (2017) [C1]

© Published by the BMJ Publishing Group Limited. Objectives Tristetraprolin (TTP), a negative regulator of many pro-inflammatory genes, is strongly expressed in rheumatoid synovia... [more]

© Published by the BMJ Publishing Group Limited. Objectives Tristetraprolin (TTP), a negative regulator of many pro-inflammatory genes, is strongly expressed in rheumatoid synovial cells. The mitogen-activated protein kinase (MAPK) p38 pathway mediates the inactivation of TTP via phosphorylation of two serine residues. We wished to test the hypothesis that these phosphorylations contribute to the development of inflammatory arthritis, and that, conversely, joint inflammation may be inhibited by promoting the dephosphorylation and activation of TTP. Methods The expression of TTP and its relationship with MAPK p38 activity were examined in non-inflamed and rheumatoid arthritis (RA) synovial tissue. Experimental arthritis was induced in a genetically modified mouse strain, in which endogenous TTP cannot be phosphorylated and inactivated. In vitro and in vivo experiments were performed to test anti-inflammatory effects of compounds that activate the protein phosphatase 2A (PP2A) and promote dephosphorylation of TTP. Results TTP expression was significantly higher in RA than non-inflamed synovium, detected in macrophages, vascular endothelial cells and some fibroblasts and co-localised with MAPK p38 activation. Substitution of TTP phosphorylation sites conferred dramatic protection against inflammatory arthritis in mice. Two distinct PP2A agonists also reduced inflammation and prevented bone erosion. In vitro anti-inflammatory effects of PP2A agonism were mediated by TTP activation. Conclusions The phosphorylation state of TTP is a critical determinant of inflammatory responses, and a tractable target for novel anti-inflammatory treatments.

DOI 10.1136/annrheumdis-2016-209424
Citations Scopus - 8Web of Science - 12
2017 Delforce SJ, Lumbers ER, de Meaultsart CC, Wang Y, Proietto A, Otton G, et al., 'Expression of renin-angiotensin system (RAS) components in endometrial cancer', ENDOCRINE CONNECTIONS, 6 9-19 (2017) [C1]
DOI 10.1530/EC-16-0082
Citations Scopus - 4Web of Science - 2
Co-authors Rodney Scott, Kirsty Pringle, E Lumbers
2016 Enjeti AK, D'Crus A, Melville K, Verrills NM, Rowlings P, 'A systematic evaluation of the safety and toxicity of fingolimod for its potential use in the treatment of acute myeloid leukaemia', Anti-Cancer Drugs, 27 560-568 (2016) [C1]

© 2016 Wolters Kluwer Health, Inc. All rights reserved. Treatment of acute myeloid leukaemia (AML) is challenging and emerging treatment options include protein phosphatase 2A (PP... [more]

© 2016 Wolters Kluwer Health, Inc. All rights reserved. Treatment of acute myeloid leukaemia (AML) is challenging and emerging treatment options include protein phosphatase 2A (PP2A) activators. Fingolimod is a known PP2A activator that inhibits multiple signalling pathways and has been used extensively in patients with multiple sclerosis and other indications. The initial positive results of PP2A activators in vitro and mouse models of AML are promising; however, its safety for use in AML has not been assessed. From human studies of fingolimod in other indications, it is possible to evaluate whether the safety and toxicity profile of the PP2A activators will allow their use in treating AML. A literature review was carried out to assess safety before the commencement of Phase I trials of the PP2A activator Fingolimod in AML. From human studies of fingolimod in other indications, it is possible to evaluate whether the safety and toxicity profile of the PP2A activators will allow their use in treating AML. A systematic review of published literature in Medline, EMBASE and the Cochrane Library of critical reviews was carried out. International standards for the design and reporting of search strategies were followed. Search terms and medical subject headings used in trials involving PP2A activators as well as a specific search were performed for 'adverse events','serious adverse events', 'delays in treatment', ' side effects' and 'toxicity' for primary objectives. Database searches were limited to papers published in the last 12 years and available in English. The search yielded 677 articles. A total of 69 journal articles were identified as relevant and included 30 clinical trials, 24 review articles and 15 case reports. The most frequently reported adverse events were nausea, diarrhoea, fatigue, back pain, influenza viral infections, nasopharyngitis and bronchitis. Specific safety concerns include monitoring of the heart rate and conduction at commencement of treatment as cardiotoxicity has been reported. There is little evidence to suggest specific bone marrow toxicity. Lymophopenia is a desired effect in the management of multiple sclerosis, but may have implications in patients with acute leukaemia as it may potentially increase susceptibility to viral infections such as influenza. Fingolimod is a potential treatment option for AML with an acceptable risk to benefit ratio, given its lack of bone marrow toxicity and the relatively low rate of serious side effects. As most patients with AML are elderly, specific monitoring for cardiac toxicity as well as infection would be required.

DOI 10.1097/CAD.0000000000000358
Citations Scopus - 5Web of Science - 4
Co-authors Anoop Enjeti
2016 Rahman MM, Rumzhum NN, Hansbro PM, Morris JC, Clark AR, Verrills NM, Ammit AJ, 'Activating protein phosphatase 2A (PP2A) enhances tristetraprolin (TTP) anti-inflammatory function in A549 lung epithelial cells', Cellular Signalling, 28 325-334 (2016) [C1]

© 2016. Chronic respiratory diseases are driven by inflammation, but some clinical conditions (severe asthma, COPD) are refractory to conventional anti-inflammatory therapies. Thu... [more]

© 2016. Chronic respiratory diseases are driven by inflammation, but some clinical conditions (severe asthma, COPD) are refractory to conventional anti-inflammatory therapies. Thus, novel anti-inflammatory strategies are necessary. The mRNA destabilizing protein, tristetraprolin (TTP), is an anti-inflammatory molecule that functions to induce mRNA decay of cytokines that drive pathogenesis of respiratory disorders. TTP is regulated by phosphorylation and protein phosphatase 2A (PP2A) is responsible for dephosphorylating (and hence activating) TTP, amongst other targets. PP2A is activated by small molecules, FTY720 and AAL(S), and in this study we examine whether these compounds repress cytokine production in a cellular model of airway inflammation using A549 lung epithelial cells stimulated with tumor necrosis factor a (TNFa) in vitro. PP2A activators significantly increase TNFa-induced PP2A activity and inhibit mRNA expression and protein secretion of interleukin 8 (IL-8) and IL-6; two key pro-inflammatory cytokines implicated in respiratory disease and TTP targets. The effect of PP2A activators is not via an increase in TNFa-induced TTP mRNA expression; instead we demonstrate a link between PP2A activation and TTP anti-inflammatory function by showing that specific knockdown of TTP with siRNA reversed the repression of TNFa-induced IL-8 and IL-6 mRNA expression and protein secretion by FTY720. Therefore we propose that PP2A activators affect the dynamic equilibrium regulating TTP; shifting the equilibrium from phosphorylated (inactive) towards unphosphorylated (active) but unstable TTP. PP2A activators boost the anti-inflammatory function of TTP and have implications for future pharmacotherapeutic strategies to combat inflammation in respiratory disease.

DOI 10.1016/j.cellsig.2016.01.009
Citations Scopus - 12Web of Science - 13
Co-authors Philip Hansbro
2016 Rahman MM, Prunte L, Lebender LF, Patel BS, Gelissen I, Hansbro PM, et al., 'The phosphorylated form of FTY720 activates PP2A, represses inflammation and is devoid of S1P agonism in A549 lung epithelial cells', SCIENTIFIC REPORTS, 6 (2016) [C1]
DOI 10.1038/srep37297
Citations Scopus - 5Web of Science - 5
Co-authors Philip Hansbro
2016 Rahman MM, Prabhala P, Rumzhum NN, Patel BS, Wickop T, Hansbro PM, et al., 'TLR2 ligation induces corticosteroid insensitivity in A549 lung epithelial cells: Anti-inflammatory impact of PP2A activators', International Journal of Biochemistry and Cell Biology, 78 279-287 (2016) [C1]

© 2016 Elsevier Ltd Corticosteroids are effective anti-inflammatory therapies widely utilized in chronic respiratory diseases. But these medicines can lose their efficacy during r... [more]

© 2016 Elsevier Ltd Corticosteroids are effective anti-inflammatory therapies widely utilized in chronic respiratory diseases. But these medicines can lose their efficacy during respiratory infection resulting in disease exacerbation. Further in vitro research is required to understand how infection worsens lung function control in order to advance therapeutic options to treat infectious exacerbation in the future. In this study, we utilize a cellular model of bacterial exacerbation where we pretreat A549 lung epithelial cells with the synthetic bacterial lipoprotein Pam3CSK4 (a TLR2 ligand) to mimic bacterial infection and tumor necrosis factor a (TNFa) to simulate inflammation. Under these conditions, Pam3CSK4 induces corticosteroid insensitivity; demonstrated by substantially reduced ability of the corticosteroid dexamethasone to repress TNFa-induced interleukin 6 secretion. We then explored the molecular mechanism responsible and found that corticosteroid insensitivity induced by bacterial mimics was not due to altered translocation of the glucocorticoid receptor into the nucleus, nor an impact on the NF-¿B pathway. Moreover, Pam3CSK4 did not affect corticosteroid-induced upregulation of anti-inflammatory MAPK deactivating phosphatase¿MKP-1. However, Pam3CSK4 can induce oxidative stress and we show that a proportion of the MKP-1 produced in response to corticosteroid in the context of TLR2 ligation was rendered inactive by oxidation. Thus to combat inflammation in the context of bacterial exacerbation we sought to discover effective strategies that bypassed this road-block. We show for the first time that known (FTY720) and novel (theophylline) activators of the phosphatase PP2A can serve as non-steroidal anti-inflammatory alternatives and/or corticosteroid-sparing approaches in respiratory inflammation where corticosteroid insensitivity exists.

DOI 10.1016/j.biocel.2016.07.030
Citations Scopus - 2Web of Science - 3
Co-authors Philip Hansbro
2016 Toop HD, Dun MD, Ross BK, Flanagan HM, Verrills NM, Morris JC, 'Development of novel PP2A activators for use in the treatment of acute myeloid leukaemia', Organic and Biomolecular Chemistry, 14 4605-4616 (2016) [C1]

© The Royal Society of Chemistry. AAL(S), the chiral deoxy analog of the FDA approved drug FTY720, has been shown to inhibit proliferation and apoptosis in several cancer cell lin... [more]

© The Royal Society of Chemistry. AAL(S), the chiral deoxy analog of the FDA approved drug FTY720, has been shown to inhibit proliferation and apoptosis in several cancer cell lines. It has been suggested that it does this by activating protein phosphatase 2A (PP2A). Here we report the synthesis of new cytotoxic analogs of AAL(S) and the evaluation of their cytotoxicity in two myeloid cell lines, one of which is sensitive to PP2A activation. We show that these analogs activate PP2A in these cells supporting the suggested mechanism for their cytotoxic properties. Our findings identify key structural motifs required for anti-cancer effects.

DOI 10.1039/c6ob00556j
Citations Scopus - 5Web of Science - 7
Co-authors Matt Dun
2016 Smith AM, Dun MD, Lee EM, Harrison C, Kahl R, Flanagan H, et al., 'Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors', Oncotarget, 7 47465-47478 (2016) [C1]

Constitutive activation of the receptor tyrosine kinase Fms-like tyrosine kinase 3 (FLT3), via co-expression of its ligand or by genetic mutation, is common in acute myeloid leuke... [more]

Constitutive activation of the receptor tyrosine kinase Fms-like tyrosine kinase 3 (FLT3), via co-expression of its ligand or by genetic mutation, is common in acute myeloid leukemia (AML). In this study we show that FLT3 activation inhibits the activity of the tumor suppressor, protein phosphatase 2A (PP2A). Using BaF3 cells transduced with wildtype or mutant FLT3, we show that FLT3-induced PP2A inhibition sensitizes cells to the pharmacological PP2A activators, FTY720 and AAL(S). FTY720 and AAL(S) induced cell death and inhibited colony formation of FLT3 activated cells. Furthermore, PP2A activators reduced the phosphorylation of ERK and AKT, downstream targets shared by both FLT3 and PP2A, in FLT3/ITD+BaF3 and MV4-11 cell lines. PP2A activity was lower in primary human bone marrow derived AML blasts compared to normal bone marrow, with blasts from FLT3-ITD patients displaying lower PP2A activity than WT-FLT3 blasts. Reduced PP2A activity was associated with hyperphosphorylation of the PP2A catalytic subunit, and reduced expression of PP2A structural and regulatory subunits. AML patient blasts were also sensitive to cell death induced by FTY720 and AAL(S), but these compounds had minimal effect on normal CD34+ bone marrow derived monocytes. Finally, PP2A activating compounds displayed synergistic effects when used in combination with tyrosine kinase inhibitors in FLT3-ITD+cells. A combination of Sorafenib and FTY720 was also synergistic in the presence of a protective stromal microenvironment. Thus combining a PP2A activating compound and a FLT3 inhibitor may be a novel therapeutic approach for treating AML.

DOI 10.18632/oncotarget.10167
Citations Scopus - 8Web of Science - 8
Co-authors Leonie Ashman, Kathryn Skelding, Matt Dun, Anoop Enjeti
2015 Gilan O, Diesch J, Amalia M, Jastrzebski K, Chueh AC, Verrills NM, et al., 'Corrigendum. PR55a-containing protein phosphatase 2A complexes promote cancer cell migration and invasion through regulation of AP-1 transcriptional activity', Oncogene, 34 1340-1340 (2015)
DOI 10.1038/onc.2014.460
Citations Scopus - 2Web of Science - 2
2015 Gilan O, Diesch J, Amalia M, Jastrzebski K, Chueh AC, Verrills NM, et al., 'PR55a-containing protein phosphatase 2A complexes promote cancer cell migration and invasion through regulation of AP-1 transcriptional activity', Oncogene, 34 1333-1339 (2015) [C1]

The proto-oncogene c-Jun is a component of activator protein-1 (AP-1) transcription factor complexes that regulates processes essential for embryonic development, tissue homeostas... [more]

The proto-oncogene c-Jun is a component of activator protein-1 (AP-1) transcription factor complexes that regulates processes essential for embryonic development, tissue homeostasis and malignant transformation. Induction of gene expression by c-Jun involves stimulation of its transactivation ability and upregulation of DNA binding capacity. While it is well established that the former requires JNK-mediated phosphorylation of S63/S73, the mechanism(s) through which binding of c-Jun to its endogenous target genes is regulated remains poorly characterized. Here we show that interaction of c-Jun with chromatin is positively regulated by protein phosphatase 2A (PP2A) complexes targeted to c-Jun by the PR55a regulatory subunit. PR55a-PP2A specifically dephosphorylates T239 of c-Jun, promoting its binding to genes regulating tumour cell migration and invasion. PR55a-PP2A also enhanced transcription of these genes, without affecting phosphorylation of c-Jun on S63. These findings suggest a critical role for interplay between JNK and PP2A pathways determining the functional activity of c-Jun/AP-1 in tumour cells.

DOI 10.1038/onc.2014.26
Citations Scopus - 7Web of Science - 7
2015 Tay KH, Liu X, Chi M, Jin L, Jiang CC, Guo ST, et al., 'Involvement of vacuolar H

© 2014 John Wiley & Sons A/S. Targeting the sphingosine 1-phosphate (S1P)/S1P receptor (S1PR) signalling axis is emerging as a promising strategy in the treatment of cancer.... [more]

© 2014 John Wiley & Sons A/S. Targeting the sphingosine 1-phosphate (S1P)/S1P receptor (S1PR) signalling axis is emerging as a promising strategy in the treatment of cancer. However, the effect of such an approach on survival of human melanoma cells remains less understood. Here, we show that the sphingosine analogue FTY720 that functionally antagonises S1PRs kills human melanoma cells through a mechanism involving the vacuolar H+-ATPase activity. Moreover, we demonstrate that FTY720-triggered cell death is characterized by features of necrosis and is not dependent on receptor-interacting protein kinase 1 or lysosome cathepsins, nor was it associated with the activation of protein phosphatase 2A. Instead, it is mediated by increased production of reactive oxygen species and is antagonized by activation of autophagy. Collectively, these results suggest that FTY720 and its analogues are promising candidates for further development as new therapeutic agents in the treatment of melanoma.

DOI 10.1111/pcmr.12326
Citations Scopus - 8Web of Science - 8
Co-authors Lei Jin, Xu Zhang, Chenchen Jiang
2015 Rahman MM, Rumzhum NN, Morris JC, Clark AR, Verrills NM, Ammit AJ, 'Basal protein phosphatase 2A activity restrains cytokine expression: role for MAPKs and tristetraprolin', SCIENTIFIC REPORTS, 5 (2015) [C1]
DOI 10.1038/srep10063
Citations Scopus - 16Web of Science - 16
2014 Goldie BJ, Dun MD, Lin M, Smith ND, Verrills NM, Dayas CV, Cairns MJ, 'Activity-associated miRNA are packaged in Map1b-enriched exosomes released from depolarized neurons.', Nucleic Acids Research, 42 9195-9208 (2014) [C1]
DOI 10.1093/nar/gku594
Citations Scopus - 55Web of Science - 57
Co-authors Christopher Dayas, Matt Dun, Murray Cairns
2014 Hatchwell L, Girkin J, Morten M, Collison A, Mattes J, Foster PS, et al., 'Salmeterol attenuates chemotactic responses in rhinovirus-induced exacerbation of allergic airways disease¿by modulating protein phosphatase 2A', Journal of Allergy and Clinical Immunology, (2014) [C1]

Background: ß-Agonists are used for relief and control of asthma symptoms by reversing bronchoconstriction. They might also have anti-inflammatory properties, but the underpinning... [more]

Background: ß-Agonists are used for relief and control of asthma symptoms by reversing bronchoconstriction. They might also have anti-inflammatory properties, but the underpinning mechanisms remain poorly understood. Recently, a direct interaction between formoterol and protein phosphatase 2A (PP2A) has been described in¿vitro. Objective: We sought to elucidate the molecular mechanisms by which ß-agonists exert anti-inflammatory effects in allergen-driven and rhinovirus 1B-exacerbated allergic airways disease (AAD). Methods: Mice were sensitized and then challenged with house dust mite to induce AAD while receiving treatment with salmeterol, formoterol, or salbutamol. Mice were also infected with rhinovirus 1B to exacerbate lung inflammation and therapeutically administered salmeterol, dexamethasone, or the PP2A-activating drug (S)-2-amino-4-(4-[heptyloxy]phenyl)-2-methylbutan-1-ol (AAL[S]). Results: Systemic or intranasal administration of salmeterol protected against the development of allergen- and rhinovirus-induced airway hyperreactivity and decreased eosinophil recruitment to the lungs as effectively as dexamethasone. Formoterol and salbutamol also showed anti-inflammatory properties. Salmeterol, but not dexamethasone, increased PP2A activity, which reduced CCL11, CCL20, and CXCL2 expression and reduced levels of phosphorylated extracellular signal-regulated kinase 1 and active nuclear factor ¿B subunits in the lungs. The anti-inflammatory effect of salmeterol was blocked by targeting the catalytic subunit of PP2A with small RNA interference. Conversely, increasing PP2A activity with AAL(S) abolished rhinovirus-induced airway hyperreactivity, eosinophil influx, and CCL11, CCL20, and CXCL2 expression. Salmeterol also directly activated immunoprecipitated PP2A in¿vitro isolated from human airway epithelial cells. Conclusions: Salmeterol exerts anti-inflammatory effects by increasing PP2A activity in AAD and rhinovirus-induced lung inflammation, which might potentially account for some of its clinical benefits. © 2013 American Academy of Allergy, Asthma & Immunology.

DOI 10.1016/j.jaci.2013.11.014
Citations Scopus - 20Web of Science - 18
Co-authors Matt Dun, Adam Collison, Paul Foster, Joerg Mattes
2014 Hoffman A, Carpenter H, Kahl R, Watt LF, Dickson PW, Rostas JAP, et al., 'Dephosphorylation of CaMKII at T253 controls the metaphase-anaphase transition', Cellular Signalling, 26 748-756 (2014) [C1]

Calcium/calmodulin-stimulated protein kinase II (CaMKII) is a multi-functional serine/threonine protein kinase that controls a range of cellular functions, including proliferation... [more]

Calcium/calmodulin-stimulated protein kinase II (CaMKII) is a multi-functional serine/threonine protein kinase that controls a range of cellular functions, including proliferation. The biological properties of CaMKII are regulated by multi-site phosphorylation and targeting via interactions with specific proteins. To investigate the role specific CaMKII phosphorylation sites play in controlling cell proliferation and cell cycle progression, we examined phosphorylation of CaMKII at two sites (T253 and T286) at various stages of the cell cycle, and also examined the effects of overexpression of wild-type (WT), T286D phosphomimic, T253D phosphomimic and T253V phosphonull forms of CaMKIIa in MDA-MB-231 breast cancer and SHSY5Y neuroblastoma cells on cellular proliferation and cell cycle progression. We demonstrate herein that whilst there is no change in total CaMKII expression or T286 phosphorylation throughout the cell cycle, a marked dephosphorylation of CaMKII at T253 occurs during the G2and/or M phases. Additionally, we show by molecular inhibition, as well as pharmacological activation, that protein phosphatase 2A (PP2A) is the phosphatase responsible for this dephosphorylation. Furthermore, we show that inducible overexpression of WT, T286D and T253V forms of CaMKIIa in MDA-MB-231 and SHSY5Y cells increases cellular proliferation, with no alteration in cell cycle profiles. By contrast, overexpression of a T253D phosphomimic form of CaMKIIa significantly decreases proliferation, and cells accumulate in mitosis, specifically in metaphase. Taken together, these results strongly suggest that the dephosphorylation of CaMKII at T253 is involved in controlling the cell cycle, specifically the metaphase-anaphase transition. © 2014 Elsevier Inc.

DOI 10.1016/j.cellsig.2013.12.015
Citations Scopus - 6Web of Science - 6
Co-authors John Rostas, Kathryn Skelding, Phil Dickson
2013 Collison AM, Hatchwell LM, Verrills NM, Wark PA, Pereira De Siqueira AL, Tooze MK, et al., 'The E3 ubiquitin ligase midline 1 promotes allergen and rhinovirus-induced asthma by inhibiting protein phosphatase 2A activity', Nature Medicine, 19 232-237 (2013) [C1]
Citations Scopus - 71Web of Science - 69
Co-authors Adam Collison, Paul Foster, Peter Wark, Joerg Mattes, Nathan Bartlett
2012 Skelding KA, Dickson PW, Verrills NM, Rostas JA, 'Progression through mitosis can be controlled by dephosphorylation of CaMKII at T253', JOURNAL OF NEUROCHEMISTRY, 123 31-31 (2012) [E3]
Co-authors Kathryn Skelding, John Rostas, Phil Dickson
2012 Bradbury P, Mahmassani M, Zhong J, Turner K, Paul A, Verrills NM, O'Neill GM, 'PP2A phosphatase suppresses function of the mesenchymal invasion regulator NEDD9', Biochimica Et Biophysica Acta-Molecular Cell Research, 1823 290-297 (2012) [C1]
DOI 10.1016/j.bbamcr.2011.10.011
Citations Scopus - 12Web of Science - 11
2012 Tay KH, Jin L, Tseng HY, Jiang CC, Ye Y, Thorne RF, et al., 'Suppression of PP2A is critical for protection of melanoma cells upon endoplasmic reticulum stress', Cell Death and Disease, 3 (2012) [C1]
DOI 10.1038/cddis.2012.79
Citations Scopus - 25Web of Science - 23
Co-authors Rick Thorne, Chenchen Jiang, Lei Jin, Xu Zhang
2011 Skelding KA, Rostas JA, Verrills NM, 'Controlling the cell cycle: The role of calcium/calmodulin-stimulated protein kinases I and II', Cell Cycle, 10 631-639 (2011) [C1]
DOI 10.4161/cc.10.4.14798
Citations Scopus - 44Web of Science - 44
Co-authors John Rostas, Kathryn Skelding
2011 Roberts KG, McDougall FK, Verrills NM, 'Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers - Response', Cancer Research, 71 2404-2404 (2011) [C3]
DOI 10.1158/0008-5472.can-10-4297
2011 Chang H-Y, Jennings PC, Stewart JL, Verrills NM, Jones KT, 'Essential role of protein phosphatase 2A in metaphase II arrest and activation of mouse eggs shown by okadaic acid, dominant negative protein phosphatase 2A, and FTY720', Journal of Biological Chemistry, 286 14705-14712 (2011) [C1]
DOI 10.1074/jbc.M110.193227
Citations Scopus - 26Web of Science - 23
2011 Verrills NM, Irwin JA, He XY, Wood LG, Powell H, Simpson JL, et al., 'Identification of novel diagnostic biomarkers for asthma and chronic obstructive pulmonary disease', American Journal of Respiratory and Critical Care Medicine, 183 1633-1643 (2011) [C1]
DOI 10.1164/rccm.201010-1623OC
Citations Scopus - 61Web of Science - 56
Co-authors Vanessa Mcdonald, Jennifer Irwin, Lisa Wood, Alistair Sim, Jodie Simpson, Peter Gibson
2010 Roberts KG, Smith AM, McDougall FK, Carpenter HC, Horan MP, Neviani P, et al., 'Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers', Cancer Research, 70 5438-5447 (2010) [C1]
DOI 10.1158/0008-5472.CAN-09-2544
Citations Scopus - 87Web of Science - 84
Co-authors Leonie Ashman, Alistair Sim
2010 Kranias G, Watt L, Carpenter HC, Holst J, Ludowyke R, Strack S, et al., 'Protein phosphatase 2A carboxymethylation and regulatory B subunits differentially regulate mast cell degranulation', Cellular Signalling, 22 1882-1890 (2010) [C1]
DOI 10.1016/j.cellsig.2010.07.017
Citations Scopus - 8Web of Science - 7
Co-authors Alistair Sim
2010 Skelding KA, Suzuki T, Gordon SL, Xue J, Verrills NM, Dickson PW, Rostas JA, 'Regulation of CaMKII by phospho-Thr253 or phospho-Thr286 sensitive targeting alters cellular function', Cellular Signalling, 22 759-769 (2010) [C1]
DOI 10.1016/j.cellsig.2009.12.011
Citations Scopus - 14Web of Science - 15
Co-authors Kathryn Skelding, John Rostas, Phil Dickson
2009 Skelding KA, Liao X, Verrills NM, Fluechter L, Dickson PW, Rostas JA, 'CaMKII phosphorylation at T253 alters neuronal growth rates and morphology', Journal of Neurochemistry, 110, Suppl. 2 42 (2009) [E3]
DOI 10.1111/j.1471-4159.2009.06238.x
Co-authors Kathryn Skelding, Phil Dickson, John Rostas
2009 Rostas JA, Skelding KA, Verrills NM, Suzuki PW, Dickson T, 'CaMKII binding partners vary with cell type and phosphorylation state', Journal of Neurochemistry, 110, Suppl. 2 40-41 (2009) [E3]
DOI 10.1111/j.1471-4159.2009.06238.x
Co-authors John Rostas, Kathryn Skelding
2008 Skelding KA, Verrills NM, Fluechter L, Sim AT, Dickson PW, Rostas JA, 'Development of a novel method for the identification of CaMKII binding proteins', Journal of Neurochemistry, 106 51 (2008) [E3]
Co-authors John Rostas, Kathryn Skelding, Alistair Sim, Phil Dickson
2008 Ong V, Liem NLM, Schmid MA, Verrills NM, Papa RA, Marshall GM, et al., 'A role for altered microtubule polymer levels in vincristine resistance of childhood acute lymphoblastic leukemia xenografts', JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 324 434-442 (2008) [C1]
DOI 10.1124/jpet.107.128926
Citations Scopus - 16Web of Science - 15
2007 Neviani P, Santhanam R, Oaks JJ, Eiring AM, Notari M, Blaser BW, et al., 'FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia', Journal of Clinical Investigation, 117 2408-2421 (2007) [C1]
DOI 10.1172/jci31095
Citations Scopus - 257Web of Science - 249
2006 Verrills NM, Po'Uha ST, Liu MLM, Liaw TYE, Larsen MR, Ivery MT, et al., 'Alterations in gamma-actin and tubulin-targeted drug resistance in childhood leukemia', Journal of the National Cancer Institute, 98 1363-1374 (2006) [C1]
DOI 10.1093/jnci/djj372
Citations Scopus - 49Web of Science - 47
2006 Verrills NM, 'Clinical proteomics: present and future prospects', Clinical Biochemist Reviews, 27 99-116 (2006) [C2]
2006 Sim AT, Ludowyke RI, Verrills NM, 'Mast cell function: Regulation of degranulation by serine/threonine phosphatases', Pharmacology & Therapeutics, 112 425-439 (2006) [C1]
DOI 10.1016/j.pharmthera.2006.04.011
Citations Scopus - 23Web of Science - 20
Co-authors Alistair Sim
2006 Verrills NM, Liem NL, Liaw TYE, Hood BD, Lock RB, Kavallaris M, 'Proteomic analysis reveals a novel role for the actin cytoskeleton in vincristine resistant childhood leukemia - an in vivo study', Proteomics, 6 1681-1694 (2006) [C1]
DOI 10.1002/pmic.200500417
Citations Scopus - 65Web of Science - 61
2005 Kavallaris M, Verrills NM, 'Improving the targeting of tubulin-binding agents: lessons from drug resistance studies', Current Pharmaceutical Design, 11 1719-1733 (2005) [C1]
DOI 10.2174/1381612053764706
Citations Scopus - 49Web of Science - 49
2005 Schevzov G, Vrhovski B, Bryce NS, Elmir S, Qiu MR, O''Neil GM, et al., 'Tissue-specific tropomyosin isoform composition', Journal of Histochemistry and Cytochemistry: imaging the spectrum of cell biology, 53 557-570 (2005) [C1]
DOI 10.1369/jhc.4A6505.2005
Citations Scopus - 85Web of Science - 79
2004 Don S, Verrills NM, Liaw TY, Liu ML, Norris MD, Haber M, Kavallaris M, 'Neuronal-associated microtubule proteins class III ß-tubulin ad MAP2c in neuroblastoma: Role in resistance to microtubule-targeted drugs', Molecular Cancer Therapeutics, 3 1137-1146 (2004) [C1]
Citations Scopus - 43Web of Science - 38
2003 Verrills NM, Kavallaris M, 'Drug resistance mechanisms in cancer cells: A proteomics perspective', Current Opinion in Molecular Therapeutics, 5 258-265 (2003) [C1]
Citations Scopus - 20Web of Science - 20
2003 Mackintosh JA, Choi HY, Bae SH, Veal DA, Bell PJ, Ferrari BC, et al., 'A fluorescent natural product for ultra sensitive detection of proteins in one-dimensional and two-dimensional gel electrophoresis', Proteomics, 3 2273-2288 (2003) [C1]
DOI 10.1002/pmic.200300578
Citations Scopus - 107Web of Science - 96
2003 Verrills NM, Walsh BJ, Cobon GS, Hains PG, Kavallaris M, 'Proteome analysis of Vinca alkaloid response and resistance in acute lymphoblastic leukemia reveals novel cytoskeletal alterations', Journal of Biological Chemistry, 278 4508-4509 (2003) [C1]
DOI 10.1074/jbc.M303378200
Citations Scopus - 63Web of Science - 60
2003 Verrills NM, Flemming CL, Liu M, Ivery MT, Cobon GS, Norris MD, et al., 'Microtubule alterations and mutations induced by desoxyepothilone B: Implications for drug-target interactions', Chemistry and Biology, 10 597-607 (2003) [C1]
DOI 10.1016/S1074-5521(03)00141-8
Citations Scopus - 98Web of Science - 93
2002 Cobon GS, Verrills N, Papakostopoulos P, Eastwood H, Linnane AW, 'The proteomics of ageing', Biogerontology, 3 133-136 (2002)

Proteomics provides an extremely powerful tool for the study of variations in protein expression between individuals, different disease states and different conditions. One of the... [more]

Proteomics provides an extremely powerful tool for the study of variations in protein expression between individuals, different disease states and different conditions. One of the major challenges facing the medical profession in the forthcoming decades is to understand the changes that occur in individuals as they become older and to attempt to develop means to improve the quality of life for the otherwise healthy ageing population. The present study describes the first phase of such an investigation in which the protein composition of human skeletal muscle samples from young and aged subjects are compared. These results provide the beginning of a Human Aged Skeletal Muscle Profile reference map which is an essential first step to further investigations.

DOI 10.1023/A:1015240304287
Citations Scopus - 16
2001 Kavallaris M, Verrills NM, Hill BT, 'Anticancer therapy with novel tubulin-interacting drugs', DRUG RESISTANCE UPDATES 4 (6): 392-401 DEC 2001, 392-401 (2001) [C1]
Citations Scopus - 106Web of Science - 97
2000 Verrills NM, Harry JH, Walsh BJ, Hains PG, Robinson ES, 'Cross-matching marsupial proteins with eutherian mammal databases: Proteome analysis of cells from UV-induced skin tumours of an opossum (Monodelphis domestica)', ELECTROPHORESIS 21 (17): 3810-3822 NOV 2000, 3810-3822 (2000) [C1]
Citations Scopus - 12Web of Science - 13
2000 Cordwell SJ, Nouwens AS, Verrills NM, Basseal DJ, Walsh BJ, 'Subproteomics based upon protein cellular location and relative solubilities in conjunction with composite two-dimensional electrophoresis gels', ELECTROPHORESIS 21 (6): 1094-1103 APR 2000, 1094-1103 (2000) [C1]
Citations Scopus - 110Web of Science - 107
2000 Bowyer J, Verrills N, Gillings MR, Holmes AJ, 'Heteroduplex mobility assay as a tool for predicting phylogenetic affiliation of environmental ribosomal RNA clones', Journal of Microbiological Methods, 41 155-160 (2000)

Heteroduplex mobility assay (HMA) of partial 16S rRNA gene fragments was tested as a tool for predicting bacterial phylogenetic relationships. Approximately 400-bp fragments were ... [more]

Heteroduplex mobility assay (HMA) of partial 16S rRNA gene fragments was tested as a tool for predicting bacterial phylogenetic relationships. Approximately 400-bp fragments were amplified from a selection of cloned environmental DNAs representing a range of sequence identities and phylogenetic relationships. Heteroduplexes between pairs of sequences were formed by mixing equal amounts of PCR products, denaturing and annealing. Annealed mixes were separated on 8% polyacrylamide gels and silver stained. Heteroduplexes were readily distinguished from reannealed homoduplex and unannealed fragments in all sequences where percentage identity was less than 95%. The heteroduplexes showed retarded electrophoretic migration with respect to homoduplexes. The relative retardation was strongly correlated to the percentage sequence identity between the two strands. The HMA is a useful tool for screening environmental clone libraries to systematically select clones representative of the phylogenetic diversity within the sample, or to selectively retrieve members of a particular phylogenetic group for more detailed study. © 2000 Elsevier Science B.V.

DOI 10.1016/S0167-7012(00)00150-0
Citations Scopus - 7
1999 Cordwell SJ, Nouwens AS, Verrills NM, McPherson JC, Hains PG, Van Dyk DD, Walsh BJ, 'The microbial proteome database - an automated laboratory catalogue for monitoring protein expression in bacteria', ELECTROPHORESIS 20 (18): 3580-3588 DEC 1999, 3580-3588 (1999) [C1]
Citations Scopus - 16Web of Science - 17
Patel BS, Rahman MM, Rumzhum NN, Oliver BG, Verrills NM, Ammit AJ, 'Theophylline Represses IL-8 Secretion from Airway Smooth Muscle Cells Independently of Phosphodiesterase Inhibition. Novel Role as a Protein Phosphatase 2A Activator.', Am J Respir Cell Mol Biol, 54 792-801 [C1]
DOI 10.1165/rcmb.2015-0308OC
Citations Scopus - 2Web of Science - 4
Show 52 more journal articles

Conference (39 outputs)

Year Citation Altmetrics Link
2017 Chen Y, Al Mazi J, Panicker N, Mannan A, Murray H, Dun M, Verrills N, 'To Quantitate DNA Damage Repair Pathways in Human Cancers VIA Establishment of a Sensitive and Quantitative Mass Spectrometry-Based Assay', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2017)
Co-authors Matt Dun
2017 Panicker N, Roselli S, Kahl R, Watt L, Verrills N, 'The Encompassing Role of Tumor Suppressive Phosphatase in Mammalian Development and Cancer', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2017)
2016 Patel BS, Rahman M, Rumzhum N, Oliver BG, Verrills NM, Ammit AJ, 'Theophylline Represses Il-8 Secretion From Asm Cells Independently Of Pde Inhibition: Novel Role As A Pp2a Activator', AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, San Francisco, CA (2016)
2016 Pearsall E, Chi M, Yoon E-J, Gilchrist J, Verrills NM, Skelding KA, 'BAALC - a new regulator of leukaemia cell survival', Amsterdam, The Netherlands (2016)
Co-authors Kathryn Skelding
2015 Pearsall E, Chi M, Yoon E-J, Gilchrist J, Verrills N, Skelding KA, 'BAALC can control the sensitivity of AML cells to chemotherapeutics', The 2015 Hunter Cancer Research Symposium Program, Newcastle (2015) [E3]
Co-authors Kathryn Skelding
2015 Ross EA, Smallie T, Naylor AJ, Desanti GE, Crowe J, O'Neil JD, et al., 'TRISTETRAPROLIN IS A NOVEL THERAPEUTIC TARGET FOR RHEUMATOID ARTHRITIS', ANNALS OF THE RHEUMATIC DISEASES (2015)
DOI 10.1136/annrheumdis-2015-207259.186
2015 Watt LF, Panicker N, Copeland B, Kahl RGS, Dun MD, Young B, et al., 'PP2A ¿ a novel biomarker and therapeutic target for poor outcome breast cancer', Proceedings of the Lowy Cancer Conference, Sydney (2015) [E3]
Co-authors Kathryn Skelding, Matt Dun
2015 Dun M, Murray H, Al-mazi J, Kahl R, Flanagan H, Smith N, et al., 'IDENTIFICATION AND SYNERGISTIC TARGETING OF FLT3-ACTIVATED PATHWAYS IN ACUTE MYELOID LEUKAEMIA', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2015) [E3]
Co-authors Anoop Enjeti, Matt Dun
2015 Al-mazi J, Dun M, Smith N, Verrills N, 'DEVELOPMENT OF NOVEL MULTIPLE REACTION MONITORING (MRM) ASSAY FOR BIOMARKER QUANTITATION IN CANCER CELLS', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2015) [E3]
Co-authors Matt Dun
2015 Lehman W, Kahl R, Flanagan H, Verrills N, Dun M, 'DETERMINING THE MECHANISM OF LEUKAEMOGENESIS INDUCED BY SHWACHMAN-DIAMOND SYNDROME (SDS) USING COMPARATIVE AND QUANTITATIVE PROTEOMICS', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2015) [E3]
Co-authors Matt Dun
2015 Li X, Flanagan H, Kahl R, Rigby C, Verrills N, Dun M, 'CHEMICAL PROTEOMICS TO IDENTIFY THE MECHANISM OF PROTEIN PHOSPHATASE 2A (PP2A) INHIBITION IN ACUTE MYELOID LEUKAEMIA (AML)', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2015) [E3]
Co-authors Matt Dun
2015 Mannan A, Panicker N, Watt L, Kahl R, Dun M, Skelding K, Verrills N, 'ROLE OF REDUCED PROTEIN PHOSPHATASE 2A SUBUNIT, B55A, EXPRESSION IN LUMINAL B BREAST CANCER CELL LINE DNA DAMAGE REPAIR PATHWAY', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2015) [E3]
Co-authors Kathryn Skelding, Matt Dun
2015 Panicker N, Watt L, Kahl R, Dun M, Greer P, Skelding K, Verrills N, 'REDUCED EXPRESSION OF PROTEIN PHOSPHATASE 2A SUBUNIT, B55A, IN BREAST CANCER DNA DAMAGE REPAIR PATHWAYS', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2015) [E3]
Co-authors Matt Dun, Peter Greer, Kathryn Skelding
2015 Rigby C, Kahl R, Flanagan H, Li X, Enjeti A, Verrills N, Dun M, 'CHARACTERISATION OF A NOVEL PP2A INHIBITORY ONCOPROTEIN IN ACUTE MYELOID LEUKAEMIA (AML)', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2015) [E3]
Co-authors Anoop Enjeti, Matt Dun
2015 Udeh R, Kahl R, Flanagan H, Verrills N, Dun M, 'IDENTIFYING THE FUNCTIONAL ROLE OF TSR, A NOVEL DRUG TARGET IN AML', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2015) [E3]
Co-authors Matt Dun
2015 Rahman M, Rumzhum NN, Clark AR, Verrills NM, Ammit AJ, 'Basal Protein Phosphatase 2a Activity Restrains Cytokine Expression In A549 Lung Epithelial Cells: Role For Mapks And Tristetraprolin', AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, Denver, CO (2015)
2014 Delforce SJ, Pringle KG, Wang Y, Verrills NM, Scott RJ, Lumbers ER, 'THE FUNCTIONAL ROLE OF THE ENDOMETRIAL RENIN ANGIOTENSIN SYSTEM IN ENDOMETRIAL CANCER', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
Co-authors E Lumbers, Kirsty Pringle, Rodney Scott
2014 Yoon E-J, Chi MN, Enjeti AK, Verrills NM, Skelding KA, 'CHARACTERISING A NEW TARGET FOR THE TREATMENT OF ACUTE LEUKAEMIAS', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
Co-authors Anoop Enjeti, Kathryn Skelding
2014 Dun MD, Kahl RGS, Flanagan H, Cairns MMJ, Smith ND, Enjeti AK, et al., 'IDENTIFICATION OF ONCOGENIC SIGNALLING PATHWAYS IN ACUTE MYELOID LEUKAEMIA (AML) PATIENTS BY PHOSPHOPROTEOMICS', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
Co-authors Matt Dun, Anoop Enjeti, Murray Cairns
2014 De Iuliis GN, Verrills NM, Dun MD, 'IN SILICO ANALYSIS OF THE TARGETS OF SMALL-MOLECULE, ANTI-CANCER COMPOUNDS FOR IMPROVED CANCER THERAPEUTICS', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
Co-authors Matt Dun, Geoffry DeiuliIs
2013 Dun MD, Smith AM, Kahl RGS, Smith ND, Khanna A, Don AS, et al., 'Unraveling the mechanism of action: drugs that activate the tumor suppressor 2A.', CANCER RESEARCH, Washington, DC (2013) [E3]
DOI 10.1158/1538-7445.AM2013-2038
Co-authors Matt Dun
2012 Skelding KA, Dickson PW, Verrills NM, Rostas JA, 'Dephosphorylation of CAMKII at T253 controls progression through metaphase', Abstracts. Australian Neuroscience Society 32nd Annual Meeting, Gold Coast, Queensland (2012) [E3]
Co-authors John Rostas, Kathryn Skelding, Phil Dickson
2011 Collison AM, Hatchwell LM, Pereira De Siqueira AL, Don A, Verrills NM, Foster PS, Mattes J, 'The development of house dust mite-induced allergic airways disease is regulated by a novel E3 ubiquitin ligase-dependent deactivation of a protein phosphatase', Respirology, Perth, WA (2011) [E3]
Co-authors Joerg Mattes, Paul Foster, Adam Collison
2011 Hatchwell LM, Collison AM, Pereira De Siqueira AL, Foster PS, Verrills NM, Don A, et al., 'A novel E3 ubiquitin ligase links rhinovirus infection to exacerbation of asthma', Respirology, Perth, WA (2011) [E3]
Co-authors Peter Wark, Joerg Mattes, Paul Foster, Adam Collison
2010 Irwin J, Verrills NM, He XY, Powell H, Wood LG, Gibson PG, 'Proteomic biomarkers as novel clinical diagnostics for airway disease', Abstract Book. Human Proteome World Congress Sydney 2010, Sydney, NSW (2010) [E3]
Co-authors Peter Gibson, Lisa Wood
2010 Verrills NM, Roberts KG, Smith AM, McDougall FK, Carpenter HC, Neviani P, et al., 'Targeting the tumour suppressor, PP2A, as a novel therapy for acute myeloid leukaemia', Sydney Cancer Conference 2010. Profiling Risk, Personalising Treatment and Predicting Outcomes. Conference Program and Abstract Book, Sydney, NSW (2010) [E3]
Co-authors Alistair Sim, Leonie Ashman
2010 Gilan O, Jastrezebski K, Diesch J, Verrills NM, Hannan RD, Dhillon AS, 'Functional regulation of the Fra-1/AP-1 Transcription factor via interactions with protein phosphatase 2A', OzBio 2010: The Molecules of Life - from Discovery to Biotechnology. Poster Abstracts, Melbourne, Australia (2010) [E3]
2010 Skelding KA, Verrills NM, Dickson PW, Rostas JA, 'Regulation of proliferation of neuroblastoma cells by CaMKII', Proceding of the Australian Neuroscience Society, Sydney, NSW (2010) [E3]
Co-authors Kathryn Skelding, John Rostas, Phil Dickson
2010 Skelding KA, Xue J, Suzuki T, Verrills NM, Dickson PW, Rostas JA, 'Mechanisms of phosphorylation-sensitive CaMKII targeting', Proceding of the Australian Neuroscience Society, Sydney, NSW (2010) [E3]
Co-authors Kathryn Skelding, Phil Dickson, John Rostas
2010 Irwin JA, Verrills NM, He XY, Powell H, Wood LG, Gibson PG, 'Proteomic biomarkers as novel clinical diagnostics for airway disease.', Sydney (2010)
Co-authors Lisa Wood, Jennifer Irwin, Peter Gibson
2009 Kranias G, Cottrell LF, Carpenter HC, Sim AT, Verrills NM, 'Protein phosphatase 2A carboxymethylation and regulatory B subunits differentially regulate mast cell degranulation', FEBS Journal, Prague, Czech Republic (2009) [E3]
Co-authors Alistair Sim
2009 Skelding KA, Liao X, Verrills NM, Fluechter L, Sim AT, Dickson PW, Rostas JA, 'Functional consequences of CaMKII phosphorylation at THR253 in neurons', ANS 2009 Abstracts: Posters, Canberra, ACT (2009) [E3]
Co-authors Phil Dickson, John Rostas, Alistair Sim, Kathryn Skelding
2009 Rostas JA, Skelding KA, Liao X, Verrills NM, Dickson PW, 'Regulation of CaMKII by targeting', Proceedings of the 2nd Australia-China Biomedical Research Conference, - (2009) [E3]
Co-authors Kathryn Skelding, Phil Dickson, John Rostas
2008 Skelding KA, Verrills NM, Fluechter L, Sim AT, Dickson PW, Rostas JA, 'Identification of CaMKII binding proteins in brain sensitive to CaMKII phosphorylation state', Proceedings of the Australian Neuroscience Society, Hobart, TAS (2008) [E3]
Co-authors Kathryn Skelding, John Rostas, Phil Dickson, Alistair Sim
2007 Roberts KG, Ashman LK, Sim AT, Verrills NM, 'Regulation of protein phosphatase 2A (PP2A) B subunits by Bcr/Abl: Potential targets for chronic myeloid leukemia', AACR Meeting Abstracts Online (Abstracts of the 98th AACR Annual Meeting), Los Angeles (2007) [E3]
Co-authors Leonie Ashman, Alistair Sim
2007 Roberts KG, Ashman LK, Sim ATR, Verrills NM, 'Altered expression of PP2A regulatory subunits in chronic myelogenous leukemia: Identifying targets for improved therapies', BLOOD, Atlanta, GA (2007)
Co-authors Leonie Ashman, Alistair Sim
2006 Chang MHY, Engelander J, Verrills NM, Tait AS, Kavallaris M, 'Differential proteomic analysis of low-level anti-microtubule resistance in acute lymphoblastic leukaemia (Poster presentation)', 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (European Journal of Cancer Supplements, Vol 4, no. 12), Prague, Czech Republic (2006) [E3]
Citations Web of Science - 1
2006 Verrills NM, Carpenter HC, Sim AT, 'Disruption of Actin-containing Protein Phosphatase 2A Complexes Regulates Cell Motility in Neuroblastoma Cells', Molecular & Cellular Proteomics, California, USA (2006) [E3]
Co-authors Alistair Sim
2004 Schevzov G, Vrhovski B, Bryce NS, Elmir S, Qiu M, Yang N, et al., 'Tropomyosin antibodies identify functionally distinct populations of actin filaments', MOLECULAR BIOLOGY OF THE CELL, Washington, DC (2004)
Show 36 more conferences
Edit

Grants and Funding

Summary

Number of grants 81
Total funding $12,269,866

Click on a grant title below to expand the full details for that specific grant.


201811 grants / $1,019,833

Hunter Cancer Biobank$397,528

Funding body: NSW Health Pathology - Pathology North

Funding body NSW Health Pathology - Pathology North
Project Team Professor Marjorie Walker, Laureate Professor Rodney Scott, Conjoint Professor Stephen Ackland, Mrs Susan Goode, Associate Professor Pradeep Tanwar, Doctor Nikki Verrills, Professor Hubert Hondermarck, Doctor Simon King, Mr Ricardo Vilain, Associate Professor Nikola Bowden, Doctor Kelly Kiejda, Associate Professor Simon Keely, Doctor Christopher Rowe
Scheme Research Grant
Role Investigator
Funding Start 2018
Funding Finish 2019
GNo G1800704
Type Of Funding C2220 - Aust StateTerritoryLocal - Other
Category 2220
UON Y

HMRI MRSP Infrastructure Funding Cancer Program 2018$183,208

Funding body: NSW Ministry of Health

Funding body NSW Ministry of Health
Project Team Conjoint Professor Stephen Ackland, Professor Xu Dong Zhang, Laureate Professor Rodney Scott, Doctor Nikki Verrills, Doctor Peter Pockney, Doctor James Lynam, Professor Christine Paul, Professor Amanda Baker
Scheme Medical Research Support Program (MRSP)
Role Investigator
Funding Start 2018
Funding Finish 2018
GNo G1800336
Type Of Funding C2220 - Aust StateTerritoryLocal - Other
Category 2220
UON Y

Switching tristetraprolin on to turn off inflammation in COPD$160,738

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Professor Alaina Ammit, Professor Andrew Clark, Doctor Nikki Verrills, Professor Phil Hansbro, Associate Professor Jonathan Morris, Professor Christine Jenkins
Scheme Project Grant
Role Lead
Funding Start 2018
Funding Finish 2020
GNo G1800321
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

Capillary Flow Two Dimensional High Pressure Liquid Chromatography (HPLC) system$75,761

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Professor Brett Nixon, Doctor Matt Dun, Doctor Nikki Verrills, Professor Hubert Hondermarck, Associate Professor Mark Baker, Doctor Elizabeth Bromfield
Scheme Equipment Grant
Role Investigator
Funding Start 2018
Funding Finish 2018
GNo G1800470
Type Of Funding Scheme excluded from IGS
Category EXCL
UON Y

Subproject: HMRI MRSP Infrastructure Funding Cancer Program 2018$65,756

Funding body: NSW Ministry of Health

Funding body NSW Ministry of Health
Project Team Conjoint Professor Stephen Ackland, Professor Xu Dong Zhang, Laureate Professor Rodney Scott, Doctor Nikki Verrills, Doctor Peter Pockney, Doctor James Lynam, Professor Christine Paul, Professor Amanda Baker
Scheme Medical Research Support Program (MRSP)
Role Lead
Funding Start 2018
Funding Finish 2018
GNo GS180006
Type Of Funding C2220 - Aust StateTerritoryLocal - Other
Category 2220
UON Y

Subproject: HMRI MRSP Infrastructure Funding Cancer Program 2018$52,000

Funding body: NSW Ministry of Health

Funding body NSW Ministry of Health
Project Team Conjoint Professor Stephen Ackland, Professor Xu Dong Zhang, Laureate Professor Rodney Scott, Doctor Nikki Verrills, Doctor Peter Pockney, Doctor James Lynam, Professor Christine Paul, Professor Amanda Baker
Scheme Medical Research Support Program (MRSP)
Role Investigator
Funding Start 2018
Funding Finish 2018
GNo GS180007
Type Of Funding C2220 - Aust StateTerritoryLocal - Other
Category 2220
UON Y

Targeting Reactive Oxygen Species Generation as a Novel Treatment Target in Acute Myeloid Leukaemia - RA support$25,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Matt Dun, Doctor Jonathan Sillar, Doctor Anoop Enjeti, Doctor Nikki Verrills
Scheme Project Grant
Role Investigator
Funding Start 2018
Funding Finish 2018
GNo G1800399
Type Of Funding C3112 - Aust Not for profit
Category 3112
UON Y

Subproject: HMRI MRSP Infrastructure Funding Cancer Program 2018$21,009

Funding body: NSW Ministry of Health

Funding body NSW Ministry of Health
Project Team Conjoint Professor Stephen Ackland, Professor Xu Dong Zhang, Laureate Professor Rodney Scott, Doctor Nikki Verrills, Doctor Peter Pockney, Doctor James Lynam, Professor Christine Paul, Professor Amanda Baker
Scheme Medical Research Support Program (MRSP)
Role Investigator
Funding Start 2018
Funding Finish 2018
GNo GS180008
Type Of Funding C2220 - Aust StateTerritoryLocal - Other
Category 2220
UON Y

Targeting DNA repair for the improved treatment of blood cancers$20,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Matt Dun, Doctor Nikki Verrills
Scheme Project Grant
Role Investigator
Funding Start 2018
Funding Finish 2018
GNo G1800611
Type Of Funding C3120 - Aust Philanthropy
Category 3120
UON Y

Subproject: HMRI MRSP Infrastructure Funding Cancer Program 2018$14,692

Funding body: NSW Ministry of Health

Funding body NSW Ministry of Health
Project Team Conjoint Professor Stephen Ackland, Professor Xu Dong Zhang, Laureate Professor Rodney Scott, Doctor Nikki Verrills, Doctor Peter Pockney, Doctor James Lynam, Professor Christine Paul, Professor Amanda Baker
Scheme Medical Research Support Program (MRSP)
Role Investigator
Funding Start 2018
Funding Finish 2018
GNo GS180004
Type Of Funding C2220 - Aust StateTerritoryLocal - Other
Category 2220
UON Y

Jennie Thomas Medical Research Travel Grant - Nikita Panicker$4,141

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Miss Nikita Panicker, Doctor Nikki Verrills, Doctor Severine Roselli, Doctor Matt Dun
Scheme Jennie Thomas Medical Research Travel Grant
Role Lead
Funding Start 2018
Funding Finish 2018
GNo G1800024
Type Of Funding C3120 - Aust Philanthropy
Category 3120
UON Y

20177 grants / $1,204,854

Novel models to advance our understanding of mammalian development$820,876

Funding body: ARC (Australian Research Council)

Funding body ARC (Australian Research Council)
Project Team Doctor Nikki Verrills, Ms Melody Coutman
Scheme Future Fellowships
Role Lead
Funding Start 2017
Funding Finish 2020
GNo G1601252
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

HMRI MRSP Cancer Research Program$189,478

Funding body: NSW Ministry of Health

Funding body NSW Ministry of Health
Project Team Conjoint Professor Stephen Ackland, Professor Xu Dong Zhang, Laureate Professor Rodney Scott, Doctor Nikki Verrills, Conjoint Associate Professor Jarad Martin, Doctor Steve Smith, Professor Christine Paul, Conjoint Professor Peter Greer, Conjoint Associate Professor Anthony Proietto, Doctor Fiona Day, Associate Professor Christopher Scarlett
Scheme Medical Research Support Program (MRSP)
Role Investigator
Funding Start 2017
Funding Finish 2017
GNo G1700603
Type Of Funding C2220 - Aust StateTerritoryLocal - Other
Category 2220
UON Y

Subproject: HMRI MRSP Cancer Research Program$78,000

Funding body: NSW Ministry of Health

Funding body NSW Ministry of Health
Project Team Doctor Nikki Verrills
Scheme Medical Research Support Program (MRSP)
Role Lead
Funding Start 2017
Funding Finish 2017
GNo GS170006
Type Of Funding C2220 - Aust StateTerritoryLocal - Other
Category 2220
UON Y

Novel models to advance our understanding of mammalian development$40,000

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Doctor Nikki Verrills
Scheme Future Fellowship Support
Role Lead
Funding Start 2017
Funding Finish 2020
GNo G1701290
Type Of Funding Internal
Category INTE
UON Y

Receptor tyrosine kinase mutations in acute myeloid leukaemia promote PP2A and p53 inhibition through the phosphorylation of SBDS$27,500

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Matt Dun, Doctor Nikki Verrills
Scheme Project Grant
Role Investigator
Funding Start 2017
Funding Finish 2017
GNo G1700272
Type Of Funding C3120 - Aust Philanthropy
Category 3120
UON Y

Determining the mechanisms underpinning leukaemic transformation for children suffering from Shwachman-Diamond Syndrome (SDS)$25,000

Funding body: Hunter District Hunting Club Inc

Funding body Hunter District Hunting Club Inc
Project Team Doctor Matt Dun, Doctor Nikki Verrills, Doctor Bryony Ross, Doctor Anoop Enjeti, Dr Jeremy Robertson
Scheme Research Funding
Role Investigator
Funding Start 2017
Funding Finish 2017
GNo G1701574
Type Of Funding C3120 - Aust Philanthropy
Category 3120
UON Y

Targeting a tumour suppressor for new cancer therapies $24,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Nikki Verrills, Doctor Matt Dun, Doctor Severine Roselli
Scheme Project Grant
Role Lead
Funding Start 2017
Funding Finish 2018
GNo G1700588
Type Of Funding C3120 - Aust Philanthropy
Category 3120
UON Y

20161 grants / $100,000

Targeting DNA repair for the improved treatment of blood cancers$100,000

Funding body: Jurox

Funding body Jurox
Project Team Doctor Matt Dun, Doctor Nikki Verrills
Scheme Research Funding
Role Investigator
Funding Start 2016
Funding Finish 2016
GNo G1601127
Type Of Funding C3120 - Aust Philanthropy
Category 3120
UON Y

20156 grants / $826,627

A novel biomarker for luminal B breast cancer$359,577

Funding body: Cancer Council NSW

Funding body Cancer Council NSW
Project Team Doctor Nikki Verrills, Doctor Kathryn Skelding
Scheme Research Grant
Role Lead
Funding Start 2015
Funding Finish 2017
GNo G1400487
Type Of Funding C3112 - Aust Not for profit
Category 3112
UON Y

High resolution fourier transform mass spectrometry platform for the discovery of novel cancer biomarkers and drug targets using label-free and isobaric-tagged approaches for quantitative proteomics.$196,250

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Professor Xu Dong Zhang, Doctor Matt Dun, Professor Jennifer Martin, Professor Hubert Hondermarck, Laureate Professor John Aitken, Doctor Nikki Verrills, Associate Professor Pradeep Tanwar, Laureate Professor Rodney Scott, Professor Maria Kavallaris, Dr Darren Saunders
Scheme Equipment Grant
Role Investigator
Funding Start 2015
Funding Finish 2015
GNo G1500935
Type Of Funding Internal
Category INTE
UON Y

Investigating the in-vitro efficacy of potential anti-CFIDS compounds in c-kit+ myeloid cells$195,800

Funding body: National CFIDS Foundation Inc.

Funding body National CFIDS Foundation Inc.
Project Team Doctor Nikki Verrills
Scheme Research Grant
Role Lead
Funding Start 2015
Funding Finish 2015
GNo G1401533
Type Of Funding International - Non Competitive
Category 3IFB
UON Y

Identification of better diagnostic tools and new treatment options for children suffering from Shwachman-Diamond Syndrome (SDS)$25,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Matt Dun, Doctor Nikki Verrills
Scheme Research Grant
Role Investigator
Funding Start 2015
Funding Finish 2015
GNo G1500757
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

A novel approach to cancer therapy - targeting patients with loss of a specific tumour suppressor gene$25,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Nikki Verrills, Doctor Kathryn Skelding
Scheme Project Grant
Role Lead
Funding Start 2015
Funding Finish 2015
GNo G1501201
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

Improving the effectiveness of a new treatment for acute myeloid leukaemia (AML)$25,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Kathryn Skelding, Doctor Mengna Chi, Doctor Nikki Verrills, Doctor Roger Liang
Scheme Project Grant
Role Investigator
Funding Start 2015
Funding Finish 2015
GNo G1600224
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

20148 grants / $977,013

Identifying novel therapeutic targets for the treatment of Acute Myeloid Leukaemia$600,000

Funding body: Cancer Institute NSW

Funding body Cancer Institute NSW
Project Team Doctor Matt Dun, Doctor Nikki Verrills, Associate Professor Martin Larsen
Scheme Early Career Fellowship
Role Investigator
Funding Start 2014
Funding Finish 2016
GNo G1300952
Type Of Funding Other Public Sector - State
Category 2OPS
UON Y

Targeting a tumour in breast cancer$142,800

Funding body: Pink Frangipani Ball Organising Committee

Funding body Pink Frangipani Ball Organising Committee
Project Team Doctor Nikki Verrills
Scheme Research Project
Role Lead
Funding Start 2014
Funding Finish 2018
GNo G1400881
Type Of Funding C3120 - Aust Philanthropy
Category 3120
UON Y

JuLI Stage $71,674

Funding body: NHMRC (National Health & Medical Research Council)

Identifying novel therapeutic targets for the treatment of Acute Myeloid Leukaemia$67,539

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Matt Dun, Doctor Nikki Verrills
Scheme Project Grant
Role Investigator
Funding Start 2014
Funding Finish 2017
GNo G1301353
Type Of Funding C3120 - Aust Philanthropy
Category 3120
UON Y

Myr-C310: A new treatment for childhood leukaemia$25,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Kathryn Skelding, Doctor Nikki Verrills
Scheme Project Grant
Role Investigator
Funding Start 2014
Funding Finish 2014
GNo G1301349
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

Preclinical testing of a novel therapeutic strategy for breast cancer $25,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Nikki Verrills, Doctor Kathryn Skelding
Scheme Project Grant
Role Lead
Funding Start 2014
Funding Finish 2014
GNo G1301439
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

Defining the role of shwachman-bodien diamond syndrome protein (SBDS) in PP2A inhibition in acute myeloid leukaemia (AML).$25,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Matt Dun, Doctor Nikki Verrills
Scheme Project Grant
Role Investigator
Funding Start 2014
Funding Finish 2014
GNo G1301442
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

Identification of BAALC as a new target for the treatment of acute myeloid leukaemia $20,000

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Doctor Kathryn Skelding, Doctor Nikki Verrills
Scheme Near Miss Grant
Role Investigator
Funding Start 2014
Funding Finish 2014
GNo G1301404
Type Of Funding Internal
Category INTE
UON Y

20135 grants / $675,312

Targeting PP2A to improve the therapeutic efficacy of mutant BRAF inhibitors in melanoma$359,253

Funding body: Cancer Council NSW

Funding body Cancer Council NSW
Project Team Professor Xu Dong Zhang, Doctor Nikki Verrills, Doctor Chen Chen Jiang
Scheme Research Grant
Role Investigator
Funding Start 2013
Funding Finish 2016
GNo G1200388
Type Of Funding C3112 - Aust Not for profit
Category 3112
UON Y

Targeting BAALC as a new treatment for acute myeloid leukaemia$25,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Kathryn Skelding, Doctor Nikki Verrills
Scheme Project Grant
Role Investigator
Funding Start 2013
Funding Finish 2013
GNo G1301348
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

Proteomics of Cancer$6,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Matt Dun, Doctor Nikki Verrills, Dr Anoop Enjeti
Scheme Project Grant
Role Investigator
Funding Start 2013
Funding Finish 2013
GNo G1300054
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

20127 grants / $455,500

Activating a tumour suppressor for leukaemia therapy$260,000

Funding body: Cancer Council NSW

Funding body Cancer Council NSW
Project Team Doctor Nikki Verrills, Dr Anthony Don, Dr Anoop Enjeti, Associate Professor Jonathan Morris
Scheme Research Grant
Role Lead
Funding Start 2012
Funding Finish 2014
GNo G1100512
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

Activating a tumour suppressor for leukaemia therapy they receive$100,000

Funding body: Cure Cancer Australia Foundation

Funding body Cure Cancer Australia Foundation
Project Team Doctor Nikki Verrills, Dr Anthony Don, Dr Anoop Enjeti, Associate Professor Jonathan Morris
Scheme Research Grant
Role Lead
Funding Start 2012
Funding Finish 2012
GNo G1200007
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

Microscopic illumination system for advanced fluorescent protein technology$34,000

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Doctor Rick Thorne, Professor Xu Dong Zhang, Professor Murray Cairns, Doctor Nikki Verrills, Doctor Charles De Bock, Doctor Jude Weidenhofer, Doctor Severine Roselli, Doctor Kathryn Skelding, Emeritus Professor Leonie Ashman, Professor Hubert Hondermarck
Scheme Equipment Grant
Role Investigator
Funding Start 2012
Funding Finish 2012
GNo G1100983
Type Of Funding Other Public Sector - Commonwealth
Category 2OPC
UON Y

Role of CaMKII targeting in neuronal susceptibility to excitotoxic cell death$20,000

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Emeritus Professor John Rostas, Professor Neil Spratt, Associate Professor Phillip Dickson, Doctor Nikki Verrills
Scheme Near Miss Grant
Role Investigator
Funding Start 2012
Funding Finish 2012
GNo G1200673
Type Of Funding Internal
Category INTE
UON Y

Activating a tumour suppressor for leukaemia therapy$20,000

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Doctor Nikki Verrills
Scheme Near Miss Grant
Role Lead
Funding Start 2012
Funding Finish 2012
GNo G1200678
Type Of Funding Internal
Category INTE
UON Y

Regulation of the cell cycle by phosphorylation dependent targeting of CaMKII$20,000

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Doctor Nikki Verrills, Doctor Kathryn Skelding, Emeritus Professor John Rostas, Associate Professor Phillip Dickson, Conjoint Professor Keith Jones
Scheme Near Miss Grant
Role Lead
Funding Start 2012
Funding Finish 2012
GNo G1200679
Type Of Funding Internal
Category INTE
UON Y

FASEB Protein Phosphatases, Snowmass, Colorado USA, 15 - 20 July 2012$1,500

Funding body: University of Newcastle - Faculty of Health and Medicine

Funding body University of Newcastle - Faculty of Health and Medicine
Project Team Doctor Nikki Verrills
Scheme Travel Grant
Role Lead
Funding Start 2012
Funding Finish 2013
GNo G1200803
Type Of Funding Internal
Category INTE
UON Y

20118 grants / $2,325,820

Molecular characterisation of TRAIL-regulated signal transduction pathways and their role in the development, persistence, and exacerbation of allergic airways disease$615,048

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Professor Joerg Mattes, Doctor Nikki Verrills
Scheme Project Grant
Role Investigator
Funding Start 2011
Funding Finish 2013
GNo G1000314
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

Targeting a tumour suppressor, PP2AS for new Leukaemia therapies$600,000

Funding body: Cancer Institute NSW

Funding body Cancer Institute NSW
Project Team Doctor Nikki Verrills
Scheme Early Career Fellowship
Role Lead
Funding Start 2011
Funding Finish 2016
GNo G1000861
Type Of Funding Other Public Sector - State
Category 2OPS
UON Y

Priority Research Centre for Cancer$555,811

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Conjoint Professor Stephen Ackland, Professor Xu Dong Zhang, Emeritus Professor John Forbes, Emeritus Professor Leonie Ashman, Associate Professor Nikola Bowden, Professor Gordon Burns, Conjoint Professor Jim Denham, Professor Hubert Hondermarck, Doctor Lisa Lincz, Doctor Jennette Sakoff, Associate Professor Peter Stanwell, Doctor Rick Thorne, Doctor Nikki Verrills
Scheme Priority Research Centre
Role Investigator
Funding Start 2011
Funding Finish 2016
GNo G1101013
Type Of Funding Internal
Category INTE
UON Y

Chemical Biology$444,961

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Professor Adam McCluskey, Doctor Warwick Belcher, Associate Professor Ian Grainge, Professor Christopher Grof, Professor Peter Lewis, Professor Eileen McLaughlin, Doctor Shaun Roman, Emeritus Professor Ray Rose, Doctor Jennette Sakoff, Doctor Nikki Verrills
Scheme Priority Research Centre
Role Investigator
Funding Start 2011
Funding Finish 2013
GNo G1100052
Type Of Funding Internal
Category INTE
UON Y

Preclinical testing of PP2A activating compounds for the treatment of childhood acute lymphoblastic leukaemia$40,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Nikki Verrills, Dr Anthony Don
Scheme Paediatric Oncology Project Grant
Role Lead
Funding Start 2011
Funding Finish 2011
GNo G1001001
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

Regulation of Breast Cancer Growth by a Novel Phosphorylation-Dependent Targeting Mechanism$35,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Kathryn Skelding, Doctor Nikki Verrills, Emeritus Professor John Rostas
Scheme Breast Cancer Project Grant
Role Investigator
Funding Start 2011
Funding Finish 2011
GNo G1001005
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

Targeting PP2A as a Novel Therapeutic Strategy for mutant FLT3* Acute Myeloid Leukaemia$25,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Nikki Verrills, Doctor Kyu-Tae Kim, Dr Anoop Enjeti
Scheme Project Grant
Role Lead
Funding Start 2011
Funding Finish 2011
GNo G1000990
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

IMPLEN NanoPhotometer pearl$10,000

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Professor Murray Cairns, Associate Professor Paul Tooney, Professor Alan Brichta, Emeritus Professor John Rostas, Emeritus Professor Patricia Michie, Conjoint Professor Keith Jones, Professor Ulli Schall, Associate Professor Phillip Dickson, Associate Professor Rohan Walker, Doctor Rick Thorne, Associate Professor Chris Dayas, Doctor Nikki Verrills, Doctor Janet Bristow, Doctor Severine Roselli, Doctor Kathryn Skelding, Doctor Jude Weidenhofer, Associate Professor Liz Milward, Doctor Charles De Bock, Doctor Julie Merriman-Jones, Doctor Jing Qin Wu, Doctor Bing Liu, Dr DAN Johnstone, Ms Belinda Goldie, Doctor Natalie Beveridge
Scheme Equipment Grant
Role Investigator
Funding Start 2011
Funding Finish 2011
GNo G1100030
Type Of Funding Other Public Sector - Commonwealth
Category 2OPC
UON Y

20104 grants / $839,000

An Integrated LC-MS-NMR facility for Applications in Proteomics and Organic Chemistry$500,000

Funding body: ARC (Australian Research Council)

Funding body ARC (Australian Research Council)
Project Team Professor Adam McCluskey, Laureate Professor John Aitken, Professor Paul Dastoor, Prof Phillip Robinson, Professor Eileen McLaughlin, Emeritus Professor Geoffrey Lawrance, Professor Marcel Maeder, Professor Hugh Dunstan, Doctor Shaun Roman, Conjoint Professor Rob Atkin, Doctor Clovia Holdsworth, Associate Professor Mark Baker, Doctor Nikki Verrills, Professor Gottfried Otting, Professor Brett Nixon, Doctor Xiaojing Zhou, Ms Megan Chircop, Doctor Warwick Belcher
Scheme Linkage Infrastructure Equipment & Facilities (LIEF)
Role Investigator
Funding Start 2010
Funding Finish 2010
GNo G0190402
Type Of Funding Scheme excluded from IGS
Category EXCL
UON Y

An Integrated LC-MS-NMR facility for Applications in Proteomics and Organic Chemistry$280,000

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Professor Adam McCluskey, Laureate Professor John Aitken, Professor Paul Dastoor, Prof Phillip Robinson, Professor Eileen McLaughlin, Emeritus Professor Geoffrey Lawrance, Professor Marcel Maeder, Professor Hugh Dunstan, Doctor Shaun Roman, Conjoint Professor Rob Atkin, Doctor Clovia Holdsworth, Associate Professor Mark Baker, Doctor Nikki Verrills, Professor Gottfried Otting, Professor Brett Nixon, Doctor Xiaojing Zhou, Ms Megan Chircop, Doctor Warwick Belcher
Scheme Equipment Grant
Role Investigator
Funding Start 2010
Funding Finish 2010
GNo G1000873
Type Of Funding Internal
Category INTE
UON Y

ABI 7500 Real Time PCR System $34,000

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Doctor Rick Thorne, Doctor Nikki Verrills, Professor Murray Cairns, Associate Professor Paul Tooney, Associate Professor Doug Smith, Professor Gordon Burns, Emeritus Professor Leonie Ashman, Conjoint Professor Keith Jones, Doctor Charles De Bock, Associate Professor Chris Dayas, Associate Professor Brett Graham, Doctor Martin Horan, Doctor Rebecca Lim, Doctor Severine Roselli, Doctor Larisa Bobrovskaya, Doctor Kathryn Skelding, Associate Professor Rohan Walker, Doctor Jude Weidenhofer, Conjoint Professor Philip Bolton, Professor Alan Brichta, Professor Robert Callister, Professor Trevor Day, Associate Professor Phillip Dickson, Professor Manohar Garg, Doctor Phil Jobling, Professor Derek Laver, Associate Professor Eugene Nalivaiko, Emeritus Professor John Rostas
Scheme Equipment Grant
Role Investigator
Funding Start 2010
Funding Finish 2010
GNo G1000055
Type Of Funding Other Public Sector - Commonwealth
Category 2OPC
UON Y

Epigenetic methylation of PP2A subunit promoters in breast cancer$25,000

Funding body: Hunter Children`s Research Foundation

Funding body Hunter Children`s Research Foundation
Project Team Doctor Nikki Verrills, Doctor Martin Horan
Scheme Research Grant
Role Lead
Funding Start 2010
Funding Finish 2010
GNo G0900148
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

20094 grants / $1,161,000

Tetraspanin proteins in prostate cancer progression and prognosis$341,000

Funding body: Cancer Council NSW

Funding body Cancer Council NSW
Project Team Emeritus Professor Leonie Ashman, Doctor Nikki Verrills, Conjoint Professor Jim Denham
Scheme Research Grant
Role Investigator
Funding Start 2009
Funding Finish 2011
GNo G0188877
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

Confocal Laser Scanning Microscopy for Live Cell Imaging$275,000

Funding body: ARC (Australian Research Council)

Funding body ARC (Australian Research Council)
Project Team Conjoint Professor Keith Jones, Professor Eileen McLaughlin, Laureate Professor John Aitken, Emeritus Professor Ray Rose, Emeritus Professor John Patrick, Conjoint Professor Christina Offler, Associate Professor David McCurdy, Emeritus Professor Leonie Ashman, Professor Gordon Burns, Professor Dirk Van Helden, Doctor Nikki Verrills, Professor Brett Nixon, Doctor Shaun Roman, Professor Yong-Ling Ruan, Doctor Rick Thorne, Professor Mike Calford
Scheme Linkage Infrastructure Equipment & Facilities (LIEF)
Role Investigator
Funding Start 2009
Funding Finish 2009
GNo G0189038
Type Of Funding Scheme excluded from IGS
Category EXCL
UON Y

20085 grants / $1,646,290

HMRI Cancer Research Program - MRSP Infrastructure$1,031,290

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Conjoint Professor Stephen Ackland, Emeritus Professor Leonie Ashman, Emeritus Professor John Forbes, Conjoint Professor Jim Denham, Conjoint Professor Peter Hersey, Professor Gordon Burns, Professor Adam McCluskey, Doctor Nikki Verrills
Scheme NSW MRSP Infrastructure Grant
Role Investigator
Funding Start 2008
Funding Finish 2009
GNo G0188622
Type Of Funding Other Public Sector - State
Category 2OPS
UON Y

PP2A: a novel target for leukaemia therapy$300,000

Funding body: Cancer Council NSW

Funding body Cancer Council NSW
Project Team Doctor Nikki Verrills, Emeritus Professor Leonie Ashman, Professor Alistair Sim, Associate Professor Danilo Perrotti, Assoc. Prof Timothy Hughes, Dr David Thomas
Scheme Research Grant
Role Lead
Funding Start 2008
Funding Finish 2010
GNo G0187694
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

Functional investigations of novel SET splice isoforms in acute myeloid leukaemia and their potential as a therapeutic target.$270,000

Funding body: Anthony Rothe Memorial Trust

Funding body Anthony Rothe Memorial Trust
Project Team Doctor Nikki Verrills
Scheme Research Grant
Role Lead
Funding Start 2008
Funding Finish 2010
GNo G0188185
Type Of Funding Donation - Aust Non Government
Category 3AFD
UON Y

Novel Alternative Splice Isoforms of the SET Oncogene in Acute Myeloid Leukaemia $25,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Nikki Verrills
Scheme Project Grant
Role Lead
Funding Start 2008
Funding Finish 2008
GNo G0188462
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

PP2A: A new target for asthma therapy$20,000

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Professor Alistair Sim, Doctor Nikki Verrills, Professor John Scott, Conjoint Professor Peter Wark
Scheme Near Miss Grant
Role Investigator
Funding Start 2008
Funding Finish 2008
GNo G0188395
Type Of Funding Internal
Category INTE
UON Y

20077 grants / $528,630

FACSAria - Fluorescence activated cell sorter$300,000

Funding body: Cancer Institute NSW

Funding body Cancer Institute NSW
Project Team Doctor Nikki Verrills, Emeritus Professor Leonie Ashman, Laureate Professor John Aitken, Professor Eileen McLaughlin, Professor Alistair Sim, Doctor Rick Thorne, Doctor Jennette Sakoff
Scheme Research Infrastructure Grants
Role Lead
Funding Start 2007
Funding Finish 2007
GNo G0187666
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

The role of protein phosphatase 2A in breast cancer$75,000

Funding body: Cure Cancer Australia Foundation

Funding body Cure Cancer Australia Foundation
Project Team Doctor Nikki Verrills
Scheme Research Grant
Role Lead
Funding Start 2007
Funding Finish 2007
GNo G0186797
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

HMRI Contribution toward FACSAria - Fluorescence activated cell sorter$52,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Nikki Verrills, Emeritus Professor Leonie Ashman, Laureate Professor John Aitken, Professor Eileen McLaughlin, Professor Alistair Sim, Doctor Rick Thorne, Doctor Jennette Sakoff
Scheme Equipment Grant
Role Lead
Funding Start 2007
Funding Finish 2007
GNo G0188207
Type Of Funding Other Public Sector - State
Category 2OPS
UON Y

Differential regulation of human mast cell degranulation by discrete forms of protein phosphatase 2A$50,000

Funding body: Asthma Foundation of New South Wales

Funding body Asthma Foundation of New South Wales
Project Team Professor Alistair Sim, Doctor Nikki Verrills, Laureate Professor Paul Foster, Conjoint Professor Peter Wark, Conjoint Professor Peter Gibson, Dr Gregory Kranias
Scheme Research Grant
Role Investigator
Funding Start 2007
Funding Finish 2007
GNo G0187247
Type Of Funding Donation - Aust Non Government
Category 3AFD
UON Y

The tumour suppressor gene, PP2A, in breast cancer and its potential as a new target for therapy$29,930

Funding body: Ramaciotti Foundations

Funding body Ramaciotti Foundations
Project Team Doctor Nikki Verrills
Scheme Research Grant
Role Lead
Funding Start 2007
Funding Finish 2007
GNo G0188055
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

Polymerase Chain Reaction (PCR) machine and Spectrophotometer$20,000

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Emeritus Professor Leonie Ashman, Professor Alistair Sim, Doctor Nikki Verrills
Scheme Equipment Grant
Role Investigator
Funding Start 2007
Funding Finish 2007
GNo G0188195
Type Of Funding Other Public Sector - Commonwealth
Category 2OPC
UON Y

American Association of Cancer Research, LA Convention Centre, Los Angeles, USA, 14/4/2007 - 18/4/2007$1,700

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Doctor Nikki Verrills
Scheme Travel Grant
Role Lead
Funding Start 2007
Funding Finish 2007
GNo G0187550
Type Of Funding Internal
Category INTE
UON Y

20066 grants / $505,157

The role of protein phosphates in regulating the cytoskeletal dynamics of cancer cells$292,062

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Doctor Nikki Verrills
Scheme Training (Postdoctoral) Fellowships - Peter Doherty Biomedical Fellowship (Australia)
Role Lead
Funding Start 2006
Funding Finish 2010
GNo G0185634
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

Live cell imaging facility$149,100

Funding body: Cancer Institute NSW

Funding body Cancer Institute NSW
Project Team Doctor Rick Thorne, Doctor Nikki Verrills, Professor Alistair Sim, Professor Gordon Burns
Scheme Research Infrastructure Grants
Role Investigator
Funding Start 2006
Funding Finish 2006
GNo G0186146
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

Investigating the functional role of altered expression and point mutations in the tumour suppressor gene PP2A$50,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Nikki Verrills
Scheme Special Competitive Research Fund for Early Career Researchers in Cancer
Role Lead
Funding Start 2006
Funding Finish 2007
GNo G0186082
Type Of Funding Not Known
Category UNKN
UON Y

Novel protein phosphatase interactions in cancer$10,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Nikki Verrills, Professor Alistair Sim
Scheme Project Grant
Role Lead
Funding Start 2006
Funding Finish 2006
GNo G0186480
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

High speed computer for a live cell imaging system$3,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Rick Thorne, Professor Gordon Burns, Doctor Nikki Verrills, Professor Alistair Sim
Scheme Equipment Grant
Role Investigator
Funding Start 2006
Funding Finish 2006
GNo G0187279
Type Of Funding Not Known
Category UNKN
UON Y

BioRad Mini-PROTEAN3 Electrophoresis system$995

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Emeritus Professor Leonie Ashman, Associate Professor Phillip Dickson, Emeritus Professor Peter Dunkley, Emeritus Professor John Rostas, Conjoint Professor Judith Scott, Professor Alistair Sim, Doctor Nikki Verrills
Scheme Equipment Grant
Role Investigator
Funding Start 2006
Funding Finish 2006
GNo G0187280
Type Of Funding Not Known
Category UNKN
UON Y

20051 grants / $2,430

Europhosphatases Conference 2005, 10-14 July 2005$2,430

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Doctor Nikki Verrills
Scheme Travel Grant
Role Lead
Funding Start 2005
Funding Finish 2005
GNo G0185546
Type Of Funding Internal
Category INTE
UON Y

20041 grants / $2,400

12th International Conference on Second Messenger and Phosphoproteins, 3-7 August 2004$2,400

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Doctor Nikki Verrills
Scheme Travel Grant
Role Lead
Funding Start 2004
Funding Finish 2004
GNo G0184543
Type Of Funding Internal
Category INTE
UON Y
Edit

Research Supervision

Number of supervisions

Completed6
Current18

Current Supervision

Commenced Level of Study Research Title Program Supervisor Type
2018 PhD Investigation of the Role of PP2A-B55a in Normal Development and Cancer PhD (Medical Biochemistry), Faculty of Health and Medicine, The University of Newcastle Principal Supervisor
2018 PhD Targeting Oxidative Stress for the Improved Treatment of Acute Myeloid Leukaemia PhD (Medical Biochemistry), Faculty of Health and Medicine, The University of Newcastle Co-Supervisor
2018 PhD Proteogenomic Characterisation of Treatment Resistance in Acute Myeloid Leukaemia with Recurring Driver Mutations PhD (Medical Biochemistry), Faculty of Health and Medicine, The University of Newcastle Co-Supervisor
2018 PhD Investigation into the Anticancer and Complementary Health Benefits PhD (Medical Biochemistry), Faculty of Health and Medicine, The University of Newcastle Co-Supervisor
2018 PhD Multifunctional Core-Shell Mesoporous Silica Nanoparticles for Lung Cancer Therapy PhD (Engineering), Faculty of Engineering and Built Environment, The University of Newcastle Co-Supervisor
2018 PhD Proteomic Analysis of Blood Based Biomarkers for the Early Detection of Colorectal Heoplasia PhD (Medical Biochemistry), Faculty of Health and Medicine, The University of Newcastle Co-Supervisor
2017 PhD Application of a Sensitive, Robust and Quantitative Parallel Reaction Monitoring (PRM) Assay for Measurement of Activated Signalling Pathways in Breast Cancers PhD (Medical Biochemistry), Faculty of Health and Medicine, The University of Newcastle Principal Supervisor
2017 PhD Molecular Characterisation of Treatment Resistance in Acute Myeloid Leukaemia. PhD (Medical Biochemistry), Faculty of Health and Medicine, The University of Newcastle Co-Supervisor
2017 PhD Drug Loaded Mesoporous Core Shell Silica Nanoparticles for Targeting and Imaging Prostate Cancer PhD (Engineering), Faculty of Engineering and Built Environment, The University of Newcastle Co-Supervisor
2016 PhD The Molecular and Cellular Analysis of Cell Lines Derived From Patients With Schizophrenia PhD (Medical Biochemistry), Faculty of Health and Medicine, The University of Newcastle Co-Supervisor
2016 PhD Reduced Expression of Protein Phosphatase 2A Subunit, PPP2R2A and its Role in Breast Cancer PhD (Medical Biochemistry), Faculty of Health and Medicine, The University of Newcastle Principal Supervisor
2016 PhD Reactive Oxygen Species Promoted Leukaemogenesis; Altered Signalling Pathways as New Drug Targets for the Improved Treatment of Acute Myeloid Leukaemia PhD (Medical Biochemistry), Faculty of Health and Medicine, The University of Newcastle Co-Supervisor
2015 PhD Identifying novel therapeutic targets for the treatment of Acute Myeloid Leukaemia PhD (Medical Biochemistry), Faculty of Health and Medicine, The University of Newcastle Principal Supervisor
2015 PhD PPP2R2A - A Novel Biomarker and Therapeutic Target for Luminal B Breast Cancer PhD (Medical Biochemistry), Faculty of Health and Medicine, The University of Newcastle Principal Supervisor
2014 PhD The Renin Angiotensin System in Endometrial Cancer PhD (Human Physiology), Faculty of Health and Medicine, The University of Newcastle Co-Supervisor
2007 PhD The role of protein phosphatases in breast cancer Biochemistry & Cell Biology, University of Newcastle Co-Supervisor
2006 PhD PP2A in mast cell function Biochemistry & Cell Biology, University of Newcastle Co-Supervisor
2006 PhD Role of PP2A in cancer Biochemistry & Cell Biology, University of Newcastle Co-Supervisor

Past Supervision

Year Level of Study Research Title Program Supervisor Type
2016 PhD Enhancing the Power of Endogenous Protein Phosphatase 2A to Combat Asthmatic Inflammation: Role for MAPKs an Tristetraprolin Pharmacy, The University of Sydney Co-Supervisor
2016 PhD The impact of precise MKP-1 regulation and modulation on cytokine expression in asthma and airways remodelling Pharmacy, The University of Sydney Co-Supervisor
2014 PhD Targeting PP2A Activation as a Novel Therapeutic Strategy for Receptor Tyrosine Kinase Driven Leukemia PhD (Medical Biochemistry), Faculty of Health and Medicine, The University of Newcastle Principal Supervisor
2012 PhD The Role of Protein Phosphatase 2A as a Tumour Suppressor in Breast Cancer PhD (Medical Biochemistry), Faculty of Health and Medicine, The University of Newcastle Principal Supervisor
2011 PhD Regulation of Mast Cell Degranulation by Protein Phosphatase 2A PhD (Medical Biochemistry), Faculty of Health and Medicine, The University of Newcastle Principal Supervisor
2010 PhD Regulation of the Tumour Suppressor PP2A by Oncogenic Tyrosine Kinases PhD (Medical Biochemistry), Faculty of Health and Medicine, The University of Newcastle Principal Supervisor
Edit

News

Pink Frangipani Ball blossoms hope for breast cancer patients

June 26, 2018

Current chemotherapy and radiation treatment options for breast cancer patients are grueling, and not all patients see positive results, however with funding raised from the 2018 Pink Frangipani Ball, Dr Nikki Verrills and her research team hope to develop rev

UON researchers awarded $4.5m in ARC fellowships

June 5, 2017

World-renowned mathematician Professor George Willis receives a $2.8m ARC Australian Laureate Fellowship.

$1m for visionary cancer researchers

May 1, 2015

Two of the University of Newcastle’s leading researchers have been awarded more than $1m to focus on discovering new methods of curbing & treating cancer.

$1 million in Cancer Council NSW project grants

January 12, 2015

Two University of Newcastle (UON) cancer researchers from the School of Biomedical Sciences and Pharmacy in the Faculty of Health and Medicine have been awa

Dr Nikki Verrills

Position

ARC Future Fellow
School of Biomedical Sciences and Pharmacy
Faculty of Health and Medicine

Focus area

Medical Biochemistry

Contact Details

Email nikki.verrills@newcastle.edu.au
Phone (02) 4921 5619
Fax (02) 4921 6903
Links YouTube
YouTube
YouTube

Office

Room LS3-46
Building Life Sciences
Location Callaghan
University Drive
Callaghan, NSW 2308
Australia
Edit